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Abstract: The world of molecular profiling has undergone revolutionary changes over
the last few years as knowledge, technology, and even standard clinical practice have
evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing
instead of tumor site of origin. Molecular profiling methodologies have likewise
changed such that tests that were performed on patients a few years ago are no
longer complete and possibly inaccurate today. As with all rapid change, medical
providers can quickly fall behind or struggle to find up-to-date sources to ensure he
or she provides optimum care. In this review, the authors provide the current state
of the art for molecular profiling/precision medicine, practice standards, and a view
into the future ahead. CA Cancer J Clin 2019;69:305-343. © 2019 The Authors. CA
A Cancer Journal for Clinicians published by Wiley Periodicals, Inc. on behalf of
American Cancer Society. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
Keywords: biomarkers, cancer, gene expression profiling, drug target, moleculartargeted therapy, molecular profiling, mutation, precision medicine, sequence analysis

Molecular Testing and Its Evolution
Comprehensive molecular profiling of patient tumors has been widely studied over
the last few years in a variety of cancers, leading to the development of a new
discipline termed “personalized” or “precision” medicine. Molecular profiling is
becoming standard practice for most patients with advanced disease, replacing the
historical treatment paradigm of prescribing standard chemotherapy based upon
the tumor’s organ of origin, histology, and stage. This approach has allowed oncologists to reorganize the way they think about cancer and to make treatment recommendations based upon genomic drivers of tumorigenesis. In some cases, this has
produced dramatic, positive outcomes, including complete remissions, even in the
setting of treatment-refractory disease, delighting both patients and their caregivers.
The molecular profiling field is evolving rapidly. We are now shifting our
focus from a few small, predictive, disease-specific, evidence-based tests—chosen
“a la carte”—to broader panel testing that measures levels of or changes in myriad
“genes or gene products.” These genomic changes can serve as biomarkers of both
response prediction (indicating tumor and patient outcome/response to a specific
therapy) and a patient’s prognosis (describing innate tumor aggressiveness, which
aligns with patient survival regardless of treatment received). Increasing numbers of biomarkers have been identified for which targeted drugs are being discovered and exploited therapeutically. Scientific advances go hand-in-hand with
technological advances, which lead to improved therapeutic choices, all of which
have garnered US Food and Drug Administration (FDA), Centers for Medicare &
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Medicaid Services (CMS), and insurance company attention.
Growing acceptance of evidence-based biomarker testing
for the purpose of targeting treatment to solid tumors has
ensued. Notably, Foundation Medicine’s FoundationOne
CDx assay, which tests for several well-known markers using
next-generation sequencing (discussed later in this review),
was recently approved by the FDA and concurrently accepted
by the CMS.1,2
To facilitate cancer therapy, it is important to distinguish
between germline abnormalities and somatic abnormalities.
A very good example of this is the recently incorporated
BReast CAncer gene (BRCA) germline testing for all patients with pancreatic cancer. Germline testing involves an
extensive coverage of BRCA, whereas current somatic testing covers only certain regions of that gene. As mutation
analysis evolves into whole exome sequencing, coverage of
germline and somatic testing will be similar if not identical.
Given the increased need for somatic testing in patients with
pancreatic cancer, it is possible that whole exome sequencing will replace germline testing in guidelines to come. As
these “standard” tests evolve, they make the choices facing
patients and providers more complex while providing hope
that harnessing this knowledge will translate into substantial
benefits for patients, including cancer cures and prevention.

Molecular Profiling and Its Methodology
Molecular profiling refers to the assessment of DNA, RNA,
and/or proteins within an individual patient’s cancer using
cells obtained from a tumor biopsy or through the capture
of tumor cells circulating in the bloodstream, with the latter being less well established as a methodology. The term
“molecular profiling” was initially applied to DNA analysis
but evolved with advances in technology to take on a broader
meaning to encompass analyses of RNA and proteins.
DNA-level alterations do not necessarily lead to biological
alterations, thus making examination at the “multiomic”
(transcriptome and proteome) level imperative. This multipronged analysis results in the generation of an inordinate

amount of data that can be processed only with the help of
bioinformatic methodology. Bioinformaticians combine a
host of scientific and mathematical data to create a computer
infrastructure that assists in the analysis and interpretation
of biological data and picks out correlations between certain
gene mutations and response to a specific therapy.3 Currently
used molecular profiling techniques are as follows:
DNA and RNA
• Polymerase chain reaction (PCR) is used to amplify and
detect DNA and RNA sequences. Standard PCR involves
the amplification of one or more copies of a chosen DNA
sequence to produce millions of copies and enable detection and analysis. Reverse transcription PCR converts
RNA templates into complementary DNA for molecular
analysis.
• In situ hybridization (ISH) localizes and determines
a specific DNA or RNA sequence in a tissue section
(in situ) or in circulating tumor cells using a labeled complementary DNA, RNA, or modified nucleic acid strand
probe. This technique detects gene deletions, amplifications, translocations, and fusions. Gene fusions commonly occur in epithelial cancers as a result of genomic
rearrangements or abnormal mRNA processing. ISH
techniques include chromogenic ISH and fluorescence in
situ hybridization (FISH).
Chromogenic in situ hybridization (CISH) uses brightfield
microscopes for label detection.
FISH uses fluorescence microscopes for label detection.
• Sanger sequencing examines strands of DNA to identify
mutations by analyzing long, contiguous sequencing
reads. This DNA sequencing takes place according to the
selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. This was the primary sequencing method used
for well over 20 years and, although it is still widely used,
next-generation sequencing (NGS) is now preferred for
multigene/variant assessment.
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• NGS is a high-throughput technique that rapidly examines
and more broadly detects DNA mutations (often used for
circulating tumor DNA), copy number variations (CNVs),
and gene fusions (using an RNA sequencing panel) across
the genome. NGS can be performed on a range of cancer
types using blood, solid tissue, and bone marrow samples.
Precise tissue collection and workup are necessary for accurate results. Laboratory regulatory agencies constantly provide updated guidance documents pertaining to the design,
development, and use of NGS-based tests, recognizing the
importance of NGS in cancer diagnostics and therapeutics.
• Pyrosequencing detects and quantifies mutations, methylation, etc, through sequencing by synthesis—a method
that performs DNA sequencing by detecting the nucleotide that is incorporated by DNA polymerase.
• Fragment analysis detects changes in DNA (eg, the length
of a specific DNA sequence) or RNA to indicate the presence or absence of an inserted or deleted genomic sequence.
Protein
• Immunohistochemistry (IHC) uses the principles of antibody binding to proteins to determine the levels of protein expression in tissue samples. Tumor-related proteins
of interest can include tumor-specific antigens, protein
products of oncogenes and tumor suppressor genes, tumor
cell proliferation markers, and enzymes.

Molecular Profiling Assays and Why Physician
Oncologists and Pathologists Should Be Familiar
With Them
Modern approaches to tumor profiling assess DNA, RNA,
and proteins to form a detailed molecular map to guide more
precise and individualized treatment decisions. Because the
field of molecular profiling is continually evolving, physician
education is vital. Clinical oncologists and pathologists benefit greatly from an understanding of the technology involved,
possibly even gaining hands-on experience in molecular profiling assays and their interpretation. Any treating physician
should know what, when, and how to test and how to make
subsequent informed, patient-personalized treatment decisions.4,5 Correct interpretation of profiling results is critical;
many fear that overinterpretation or misinterpretation will
lead to treatment of patients with ineffective but expensive
therapies, negatively affecting not only patient lives but also
the health care budget. Laboratories offering broad molecular profiling services should be suitably Clinical Laboratory
Improvement Amendments (CLIA)–certified for this exact
purpose to ensure quality control (see CLIA-approved laboratories offering molecular panel analysis, below). However,
even CLIA-certified laboratories do not use identical methodologies and techniques, which can still lead to variable
results. Reproducibility is key, and the rationale behind assay

cutoff limits should be strong. Even before a patient sample is submitted for profiling, the pathologist or the treating physician—whoever plays the lead role in any particular
institution—must ensure quality-controlled tissue sample
collection.6,7 Reputable molecular testing laboratories will
advise on the exact set of tumor profiling tests to perform,
how to process samples, and how to interpret the final generated report, which is created to inform physicians of treatment choices for their patients. Still, physician education is
key to such a critical set of processes.

Biomarker Testing in the Clinic
Targeted therapies are showing efficacy in the right subgroups
of patients. Of course, these subgroups must be defined, and
this process is becoming more accurate and efficient with
evolving molecular testing methods and broader use in
research and in the clinic. As this process improves, treatment options will improve for an increasing number of
patients while eventually emerging as a more cost-effective,
generally beneficial option compared with the currently
accepted trial-and-error treatment model.
The biomarker information within Tables 1 through 2.12 is
based mainly on the National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines in Oncology (NCCN
Guidelines), NCCN Biomarkers Compendium (NCCN.org,
Accessed February 6, 2019), and FDA recommendations and
approvals (for the full definitions of all genes, please see the
Supporting Information). Although the NCCN Biomarkers
Compendium details not only predictive but also prognostic,
diagnostic, screening, monitoring, and surveillance markers, the
focus of this current review is on predictive biomarkers that can
be used to guide treatment decisions. Within Tables 1 through
2.12, the classifications in the “evidence” columns are based on
the level of clinical evidence available and the degree of consensus
among NCCN panel and other experts. In some cases, clinical
evidence comes from large, well-designed, randomized
controlled trials, but in many cases, it is mostly based on data
from indirect comparisons among randomized trials, phase 2
or nonrandomized trials, multiple smaller trials, retrospective
studies, or merely clinical observations. In some cases, substantial clinical data are lacking and evidence comes from clinical experience alone. On the basis of all these factors and how
compelling the data are, the evidence is rated as:
1. Based upon high-level evidence, there is uniform
NCCN and other expert consensus that the intervention is
appropriate (high-level, wide acceptance).
2A. Based upon lower level evidence, there is uniform
NCCN and other expert consensus that the intervention is
appropriate (lower level, wide acceptance).
2B. Based upon lower level evidence, there is some
NCCN and other expert consensus that the intervention is
appropriate (lower level, limited acceptance).
VOLUME 69 | NUMBER 4 | JULY/AUGUST 2019
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PCR, NGS

Where applicable, dMMR and MSI-H tests are used
together to identify whether a patient should undergo
further mutation testing for Lynch syndromeb

See Microsatellite Instability-High
Tumors and DNA Mismatch
Repair in the text
Testing (changes in short
repeated DNA sequences)
MSI

dMMR and MSI-H tests on available tissue are
recommended to predict response to pembrolizumaba

Where applicable, dMMR and MSI-H tests are used
together to identify whether a patient should undergo
further mutation testing for Lynch syndromeb
NGS
Mutation (= dMMR
expression)
MLH1, MSH2, MSH6,
or PMS2

MMR
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Abbreviations: dMMR, deficient mismatch repair; IHC, immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability; MSI-H, microsatellite instability-high; NGS, next-generation sequencing; PCR, polymerase chain reaction.
a
Nivolumab alone or in combination with ipilimumab may also be an option for patients with colorectal cancer.
b
dMMR is a characteristic feature of Lynch syndrome, which can play a part in patients (particularly younger patients) with cancers of the gastrointestinal tract (particularly colorectal), endometrium, ovary, brain, breast,
and renal pelvis. In Lynch syndrome, dMMR leads to insufficient repair of repetitive DNA sequences and thus a higher risk of multiple malignant tumors.

All
Lower level, wide
acceptance

All
Lower level; wide
acceptance
dMMR and MSI-H tests on available tissue are
recommended to predict response to pembrolizumaba
IHC
See Microsatellite Instability-High
Tumors and DNA Mismatch
Repair in the text
Expression

TEST DETECTS
BIOMARKER

TABLE 1.

Predictive Microsatellite Instability/Mismatch Repair Testing for Any Solid Tumor

RECOMMENDATIONS
TECHNOLOGY
WHEN

EVIDENCE

CANCER TYPE
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Infrequent but Important Site-Agnostic Biomarkers
Microsatellite instability-high tumors and DNA mismatch
repair
Microsatellite instability (MSI) is the result of inactivation of the DNA mismatch repair (MMR) system and is
characterized by a high frequency of frameshift mutations
in microsatellite DNA. In a portion of tumors, MSI is
caused by germline mutations in one of the MMR genes
(MLH1, MSH2, MSH6, or PMS2), which results in hereditary Lynch syndrome. However, the majority (80%) of MSI
cases are sporadic, often because of hypermethylation of the
MLH1 gene promoter.8,9
MSI-high (MSI-H) has been found in as many as
24 primary cancer types, most of which are displayed in
Table 3,10,11 and appears to be a generalized cancer phenotype in about 4% of all adult cancers. Tumor MSI-H
status is prognostic (patients with early-stage cancers that
are MSI-H have a better prognosis than those with microsatellite stable tumors) as well as predictive—many
MSI-H tumors are exquisitely sensitive to PD-1/PD-L1
inhibitors.12,13
At present, the FDA has granted approval for practitioners to administer the PD-1 inhibitor pembrolizumab
for the treatment of patients with unresectable or metastatic, MSI-H or MMR-deficient (dMMR) solid tumors
(site-agnostic). Currently, the approval is for patients with
tumors that have progressed after prior treatment who have
no satisfactory alternative treatment options, as well as for
patients with MSI-H or dMMR colorectal cancer (CRC)
after progression on a fluoropyrimidine, oxaliplatin, and
irinotecan, and in the first line for non–small cell lung cancer (NSCLC).14,15 In 2017, the FDA granted accelerated
approval of single-agent nivolumab, another PD-1 inhibitor, for the treatment of adult and pediatric patients older
than 12 years with MSI-H or dMMR CRC. Subsequently,
in 2018, the FDA granted accelerated approval to a combination of nivolumab plus ipilimumab (a CTLA-4 inhibitor)
for treatment of the same set of patients.16,17 See Table 1 for
MSI/MMR biomarker testing recommendations.
Neurotrophic receptor tyrosine kinase
Members of the neurotrophic receptor tyrosine kinase
(NTRK) fusion oncogene family, NTRK1/NTRK2/
NTRK3, are most prevalent in rare adult cancer types and
in several pediatric cancers, although they can occur in a
very small proportion (approximately 1%) of commonly occurring cancer types in adults, including NSCLCs, CRCs,
head and neck cancers, thyroid cancers, bladder cancers,
gliomas, and malignant melanomas (Table 418). NTRK1,
NTRK2, and NTRK3 fusions and the proteins they encode (neurotrophin receptor kinase A [TRKA], TRKB,
and TRKC, respectively) are observed at an increased frequency in highly aggressive cancers such as glioblastoma

Gene fusion

ALK
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Mutation

Amplification, mutation

Fusion, rearrangement

HER2

MET

RET

Any time

Any time

Any time

Metastatic workup

Metastatic workup

Metastatic workup

Metastatic workup

Metastatic workup

Metastatic workup

Metastatic workup

Metastatic workup

Together with EGFR
testing in “never
smokers” or small/
mixed histology
specimens

Metastatic workup

WHEN
a

NGS, FISH, RT-PCR

NGS, FISH

NGS, multiple mutation testing

NGS, pyrosequencing,
AS-PCR

Gene sequencing

NGS, multiple mutation testing

NGS, FISH, RT-PCR

NGS, multiple mutation testing

NGS, multiple mutation testing

NGS, multiple mutation testing

NGS, multiple mutation testing

IHCb

FISH, NGS, RT-PCR

TECHNOLOGY

Lower level, wide acceptance
Lower level, limited acceptance
Lower level, wide acceptance
Lower level, wide acceptance

Emerging targeted agents19; responsive
to combined BRAF and MEK inhibition
Emerging targeted agents20
Emerging targeted agents21
Emerging targeted agents22,23

All NSCLC

All NSCLC

All NSCLC

All NSCLC

All NSCLC

Adenocarcinoma, large cell, NSCLC,
squamous cell NOS

Lower level, wide acceptance
Lower level, wide acceptance

Adenocarcinoma, large cell, squamous
cell, NSCLC NOS

Lower level, wide acceptance

Squamous cell

Lower level, wide acceptance

Squamous cell
Adenocarcinoma, large cell, NSCLC NOS

Lower level, wide acceptance
High-level, wide acceptance

Adenocarcinoma, large cell, NSCLC NOS

Squamous cell

Lower level, wide acceptance
High-level, wide acceptance

Adenocarcinoma, large cell, NSCLC NOS

Adenocarcinoma, large cell, NSCLC NOS

Squamous cell

Adenocarcinoma, large cell, NSCLC NOS

CANCER TYPE

High-level, wide acceptance

High-level, wide acceptance

Lower level, wide acceptance

High-level, wide acceptance

EVIDENCE

Resistance to EGFR TKIs. Gives poor
prognosis compared with KRAS wt

Response to pembrolizumab in first-line;
FDA approved treatment15

Responsive to ROS1 TKIs

Likely resistant to EGFR TKIs

Sensitive to EGFR TKIs

Sensitive to EGFR TKIs

Resistant to EGFR TKIs

Response to oral ALK TKIs, eg, crizotinib

Response to oral ALK TKIs; alectinib has
improved efficacy over crizotinib in
first line

RECOMMENDATIONS

Abbreviations: AS-PCR, allele-specific polymerase chain reaction; FDA, US Food and Drug Administration; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; NOS, not
otherwise specified; NSCLC, non–small cell lung cancer; PD-L1, programmed death 1 ligand; RT-PCR, reverse transcription-polymerase chain reaction; TKIs, tyrosine kinase inhibitors; wt, wild type.
a
FISH is the US Food and Drug Administration-approved method for ALK gene rearrangement. NGS and RT-PCR currently are not used widely in clinical practice.
b
IHC can be used as a good alternative to FISH.24

Mutation, V600E

BRAF

Fusion rearrangement

ROS1

Mutation

Insertion mutation

EGFR exon 20
7p12

KRAS

Deletion

EGFR exon 19

Protein expression
≥50%

Mutation

EGFR exon
21 (L858R,
L861), exon 20
(S768I), exon 18
(G719X, G719)

PD-L1

Mutation

EGFR T790M

Fusion protein
expression

TEST DETECTS

BIOMARKER

TABLE 2.1. Currently Recommended Molecular Testing for NSCLC
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TABLE 2.2. Currently Recommended Predictive Molecular Testing for Colon and Rectal Cancers
TEST
DETECTS

BIOMARKER

KRAS/NRAS

BRAFa

a

Mutation

Mutation
V600E

WHEN

Workup for
metastatic
disease
(suspected or
proven)

Workup for
metastatic
disease
(suspected or
proven)

TECHNOLOGY

NGS

b

RECOMMENDATIONS

EVIDENCE

CANCER TYPE

Avoid cetuximab or
panitumumab treatment
in patients who have
tumors with KRAS and
NRAS mutations (exons
2, 3, and 4 in both)

NCCN indicate lower
level, wide
acceptance, but
many believe
classification is
high-level, wide
acceptance

Metastatic synchronous
adenocarcinoma (any T,
any N, M1),
suspected or
documented; or

NCCN indicates lower
level, wide
acceptance, but
many believe
classification is
high-level, wide
acceptance

Metastatic synchronous
adenocarcinoma (any T,
any N, M1),
suspected or
documented; or

NGS, pyrosequenc- Cetuximab or panituing, AS-PCRb
mumab treatment is not
recommended in patients
who have tumors with
BRAF V600E mutations
unless given with a BRAF
inhibitor such as
vemurafenib
The use of irinotecan in
combination with
cetuximab or panitumumab plus vemurafenib
is recommended in all
patients with previously
treated mCRC

Metachronous
metastases by CT, MRI,
and/or biopsy,
documented

Metachronous
metastases by CT, MRI,
and/or biopsy,
documented

Abbreviations: AS-PCR, allele-specific polymerase chain reaction; CT, computed tomography; mCRC, metastatic colorectal cancer; MRI, magnetic resonance
imaging; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; PCR, polymerase chain reaction.
a
KRAS and NRAS are determined alongside BRAF mutations.
b
Testing can be performed on primary and/or metastatic colorectal tissue specimens.

multiforme, and recognition of their potential oncogenic
activity led to the use of this fusion family as a predictive
biomarker as well as a drug target.25
Larotrectinib is an oral and highly selective TRK inhibitor that was granted accelerated approval by the FDA
on November 26, 2018, for the treatment of adult and
pediatric patients with metastatic or unresectable solid
tumors that have an NTRK fusion without a known
acquired resistance mutation (NTRK kinase domain
mutations, including solvent front mutations). Patients
must have a cancer that has progressed after treatment
and/or have no satisfactory alternative treatment for their
d isease. 26 The approval of larotrectinib is the second tissueagnostic FDA approval, after pembrolizumab, for the
treatment of cancer.
Another TRK inhibitor named entrectinib (RXDX101) was granted a breakthrough therapy designation by
the FDA in 2017, although it has not yet been approved
for use as a treatment for adult and pediatric patients who
have NTRK-positive, locally advanced or metastatic solid
tumors that have either progressed after prior therapies or
have no acceptable standard therapy options.27,28
NTRK fusion testing has evolved massively over the
last year or 2, and new discoveries are constantly being
made using a range of different assays. The NTRK
310
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fusions displayed in Table 418 are taken from a study that
was originally published in 2018. Although comprehensive at the time, this table does not contain the complete
list of fusions known today, in 2019. IHC has been used
as an initial screening tool to inform highly sensitive but
less available and more expensive molecular testing methodologies. 29-31 However, it is now clear that IHC does
not have sufficient sensitivity to detect all existing NTRK
fusion-encoded proteins, meaning that tumor samples
should certainly be assayed using FISH or NGS from
the get-go.18 In conclusion, clinicians need to be aware
of all 3 TRK targets and arrange adequate testing for all
of them.
Germline alterations and their testing
Gene mutations can be somatic or germline; the former
spontaneously occur after birth, and the latter are inherited (ie, present at birth). Tumor genetic (somatic) testing
detects mutations that may actually be germline alterations,
but germline alterations require confirmation in matched
normal samples (eg, DNA extracted from white blood cells,
buccal swabs, or cultured skin fibroblasts) from the tumorbearing host. Suspected germline mutations and genetic
testing are relevant to cancer treatment and prevention.
There is potential for patients to develop tumors at other

CA CANCER J CLIN 2019;69:305–343

sites or for family members to develop cancer, particularly
early-onset malignancies.
Table 532 lists the somatic mutations that may be germline. This table indicates the cancer types for which germline testing should be carried out if the specified somatic
mutations are found in a patient’s tumor profile.
There are 3 main categories of tumor genetic modifications with wide variation in the expectation that
these ref lect germline changes. The first comprises
common tumor mutations associated with rare germline
alterations. For example, mutations in TP53 are found
in greater than 60% of lung cancers. 33 Although TP53
mutations can be inherited in the Li-Fraumeni syndrome,
such familial syndromes are rare. It is believed for the
most part that there is little need for germline testing
unless the personal or family history is suggestive of such
a syndrome. The second category comprises moderately
common somatic mutations that may be associated with
familial syndromes. For example, in colon cancer, dMMR
is found by routine MSI or IHC testing in about 12%
of tumors. 34 Molecular germline testing demonstrates
that about one-quarter of these dMMR alterations are
inherited. Hence tumor testing should lead to germline
confirmation in patients and possibly further evaluation
of family members. The final category comprises uncommon tumor mutations that often ref lect germline mutations. As an example, patients with breast and ovarian
cancers regularly have germline testing done for BRCA1
and BRCA2, especially if the personal or family history
is suggestive. With routine molecular genetic tumor
testing, BRCA1/BRCA2 mutations are being found in
patients with other tumors where it is less expected. An
analysis of 100 patients with pancreatic cancer found that
7 had mutations in BRCA2, 4 of which were in the germline. 35 Finding BRCA1/BRCA2 mutations in the tumor
may aid in choosing therapy but requires germline testing
for confirmation and consideration of genetic counseling
for the family.
It has generally been considered that germline testing is
not always needed if somatic tumor testing has been done.
However, it must be kept in mind that molecular genetic
tumor testing can miss a small percentage of inherited
cases, where mutations are outside the hotspots covered in
the somatic panel or large-scale deletions and duplications
have occurred. Conversely, larger gene panel profiling may
actually identify previously unknown, clinically relevant
alterations that are germline, either de novo or inherited
from parents, despite a lack of associated clinical history. 36
In conclusion, taking into consideration the increasing availability of germline testing and whole exome
sequencing to identify inheritable mutations, as well
as the personal and family history of cancer and the

potential need for genetic counseling, medical teams
can help provide better treatment selection for patients
with some types of cancer and help to create a systematic
approach to hereditary risk.

Disease-Specific Biomarkers
In the subsections below and in Tables 2.1 through 2.12, we
address the currently accepted genes or gene products that
act as predictive biomarkers (and risk assessment markers in
some cases) for each specific solid tumor. Details on when
in the disease course the presence or levels of these markers should be assessed are also included. Under each of the
following subsections, we also include some description of
pertinent biomarkers in research. Compelling evidence suggests that these biomarkers will be listed in the NCCN “recommended” biomarker category in the foreseeable future.
Lung cancers
Lung cancer therapy continues to follow the genomic
testing paradigm (see Table 2.115,19-24). All patients with
NSCLC should be tested for EGFR, ALK, ROS1, BRAF,
and PD-L1 at baseline before treatment. Patients with
uncommon mutations of EGFR may also be treated with
tyrosine kinase inhibitor therapy. Other recommended
markers of interest include EGFR insertion 20 mutations,
RET rearrangements, and MET exon 14 mutations. All of
these targets are still being actively investigated in clinical
studies and hold potential for patient treatment.
Gastrointestinal cancers
Colon and rectal cancers. Oncologists now recommend the
assessment of several predictive markers in patients with
CRCs (see Table 2.2). The ideal time to perform genomic
testing for treatment purposes is a matter of some controversy
and varies depending on disease stage. At the time of initial
diagnosis of a stage I, II, or III tumor, it is reasonable to
perform MSI testing. Patients with MSI-H, locally confined
tumors have a better prognosis, and recommendations
are for patients with MSI-H stage II tumors to forgo
adjuvant therapy. 37,38 Additional evidence suggests
that 5-fluorouracil (5-FU) and related agents, such as
capecitabine, can actually worsen outcomes when delivered
as single agents to patients with early-stage MSI-H
CRCs. 39,40 Treatment with an oxaliplatin regimen is the
standard of care recommended for MSI-H stage III CRCs.
Finally, guidelines now recommend universal MSI testing
in all stages of CRC to determine whether patients have a
germline mutation indicative of Lynch syndrome.41 If both
the tumor DNA and the patient’s germline DNA harbor
an MMR defect, this indicates that the patient has Lynch
syndrome. Oncologists need to refer these patients for
genetic counseling and a discussion about potential testing
of relatives. Such individuals should have screening for
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TABLE 2.3. Currently Recommended Predictive Molecular Testing for Gastric, Esophageal, and Gastroesophageal Junction
Cancers
BIOMARKER

TEST DETECTS

WHEN

TECHNOLOGY

RECOMMENDATIONS

EVIDENCE

CANCER TYPE

HER2

Gene
amplification

Workup any time

(F)ISH

Particularly if trastuzumab therapy is being
considered

Lower level, wide
acceptance

Gastric, esophageal,
and gastroesophageal junction
cancers

PD-L1 (CD274)
and HER2
protein

Expression

Workup any time
for suspected or
documented, inoperable, locally advanced,
recurrent, or metastatic
adenocarcinoma

IHC, FISH

HER2-negative status
corresponds with higher
PD-L1 expression rates;
together with MMR,
HER2 is a potential
biomarker for anti–PD-L1
therapy

Lower level, wide
acceptance

Gastric, esophageal,
and gastroesophageal junction
cancers

Abbreviations: dMMR, deficient mismatch repair; (F)ISH, (fluorescence) in situ hybridization; IHC, immunohistochemistry; MMR, mismatch repair; PD-L1,
programmed death-1 ligand.
a
Patients who have gastric cancer with dMMR and HER2-negative status exhibited higher PD-L1 expression rates. These findings indicate that MMR and HER2 status might be potential biomarkers for anti–PD-L1 therapy. Pembrolizumab treatment is approved for patients whose (gastric) tumors express PD-L142 (levels ≥1
using the US Food and Drug Administration-approved IHC test).

Lynch syndrome–associated cancers at an earlier age, and
more intensive screening is called for than is recommended
for individuals without such a cancer susceptibility
mutation. There is additional evidence that the use of
aspirin can reduce premalignant polyp formation in patients
and their relatives with MSI-H tumors.43 Aspirin has also
been associated with improved outcomes in patients with
tumors that harbor PIK3CA mutations, suggesting a
potential value for assessment of mutations in that gene.44
MSI testing is also an eligibility requirement for the
current US intergroup trial of combined 5-FU, leucovorin,
and oxaliplatin (FOLFOX) with or without atezolizumab,
a PD-1 inhibitor, in patients with MSI-H stage III colon
cancer.
In patients with advanced CRC, MSI testing is also indicated at diagnosis. Mutations in or overexpression of additional genes that are predictive of outcomes include BRAF,
HER2, KRAS, NRAS, NTRK, POLE, PIK3CA, PTEN,
and RSP03. Often, other than for RAS mutations, the optimal time for this testing is when tumors become refractory
to standard chemotherapy so that the assessment reflects
the current status of the disease. Patients with MSI-H
tumors are now eligible for therapy with PD-1–targeting,
PD-L1–targeting, and/or CTLA-4–targeting immunotherapies after their disease becomes refractory to standard
chemotherapy. Those with NTRK fusions are candidates
for treatment with larotrectinib.26 Individuals whose
tumors harbor an RAS mutation are insensitive to treatment with and should not receive an anti-EGFR–targeted
monoclonal antibody such as cetuximab or panitumumab.45
It is likely that additional genomic analyses that are currently underway or to be evaluated in future studies, involving whole genome or whole exome sequencing in cohorts of
patients with known outcomes, will identify other mutations that have either prognostic or predictive utility.
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BRAF as a CRC prognostic factor. BRAF mutational status
is used as a strong predictor for overall survival (OS) at all
stages of disease; patients with BRAF-mutated CRC have
a generally poor prognosis.46-52BRAF V600E is the best
known mutation assessed using NGS.53 Compared with
patients who have CRC with BRAF wild-type tumors,
patients whose tumors manifest a BRAF mutation are
generally older and more likely to be female. Such patients
commonly have higher grade cancers at diagnosis, with
a primary tumor that is more likely to be right-sided and
to have a higher number of cancer-involved lymph nodes.
These BRAF-mutated tumors are also more likely to be
MSI-H.54
Gastric, esophageal, and gastroesophageal junction
cancers. See Table 2.3.42
Pancreatic cancers. See Table 2.4.
Genitourinary cancers
Bladder cancers. In The Cancer Genome Atlas extended
2017 study carried out by Robertson et al, findings from the
complete cohort of 412 muscle-invasive bladder cancer cases
revealed that mutations in the DNA repair genes ATM
(n = 57; 14%) and ERCC2 (n = 40; 10%), and deletions in
RAD51B (n = 10; 2%) were significant.55
It was found that all nonsilent somatic ERCC2 mutations were missense, and many could be mapped within the
conserved helicase domain. Dominant negative effects on
ERCC2 function were observed.56 Thus, bladder cancer
missense mutations in ERCC2 were associated with improved
response to cisplatin-based chemotherapy. However, ERCC2
mutations are distributed across the gene, and the functional
impact of most individual ERCC2 mutations is unknown.
Recently, Li et al reported developing a microscopy-based
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TABLE 2.4. Currently Recommended Predictive Molecular Testing for Pancreatic Cancers
BIOMARKER

TEST DETECTS

WHEN

TECHNOLOGY

RECOMMENDATIONS

EVIDENCE

CANCER TYPE

BRCA1 and
BRCA2

Mutation
(somatic and
germline)

Initial workup if the
patient has a
strong family
history on initial
diagnosisa

NGS

A known germline mutation
could help guide therapy
(eg, PARP and other DDR
enzyme inhibitors). In
October 2018, olaparib
was approved for the
treatment of patients with
germline BRCA-mutated,
metastatic pancreatic
cancer that has not
progressed after first-line,
platinum-based
chemotherapy

Nine percent of pancreatic
cancers harbor a germline or
somatic BRCA1 or BRCA2
mutation, and this has an
impact on response to
therapy. BRCA testing in
patients who are still
responsive to cytotoxic
therapy is becoming
standard practice. The use of
PARP inhibitors, specifically
olaparib, in these patients is
an option

Pancreatic
adenocarcinoma

Abbreviations: DDR, DNA damage repair; NGS, next-generation sequencing; PARP, poly(adenosine diphosphate-ribose) polymerase.
a
Having at least one close relative with prostate cancer (possibility of germline mutations) and/or at least one close relative with breast, ovarian, or pancreatic
cancer (possibility of a BRCA2 germline mutation) or with colorectal, endometrial, gastric, ovarian, pancreatic, small bowel, urothelial, kidney, or bile duct cancer
(possibility of Lynch syndrome through germline mutations in MLH1, MSH2, MSH6, or PMS2) is a risk-factor.

assay that measures the nucleotide excision repair function
of clinically observed ERCC2 mutations. Most helicase
domain mutations impaired the function. In addition, a
preclinical ERCC2-deficient bladder cancer model showed
that ERCC2 loss was sufficient to drive cisplatin sensitivity.
Thus, ERCC2 was concluded to be a predictive biomarker in
bladder cancer. Moreover, this study underscores the importance of combining genomic and functional approaches in a
co-clinical trial to guide precision oncology for conventional
chemotherapy agents. Current evidence presented here
supports the idea that ERCC2 and ATM are potentially
useful markers in muscle-invasive bladder cancer.55-57
Prostate cancers. It was recently reported that patients with
metastatic castration-resistant prostate cancer (mCRPC)
harboring germline mutations in BRCA1/BRCA2 and ATM
have superior clinical outcomes after first-line treatment
with abiraterone and enzalutamide (see Table 2.5).58 The
authors suggested that this improved response is likely driven
by mutations in BRCA1, BRCA2, and ATM. Because these
conclusions were based on only 9 patients harboring BRCA/
ATM germline mutations and the study was not entirely
prospective, these findings require prospective validation in
larger patient cohorts. A separate, small, retrospective study
found that all responders to poly(adenosine diphosphate
[ADP]-ribose) polymerase (PARP) inhibitor therapy
harbored BRCA2 mutations, whereas nonresponders did
not.59 However, it was agreed that the functional relevance
of mutations in DNA repair genes other than BRCA2
should be considered before committing to PARP inhibitor
therapy.
At the American Society of Clinical Oncology 2018
meeting, De Bono et al60 reported preliminary findings from
the KEYNOTE-199 phase 2 trial comparing responses
to the immune checkpoint inhibitor pembrolizumab

in patients who had mCRPC with or without tumor
expression of PD-L1. Thus, pembrolizumab showed antitumor activity and disease control with acceptable safety in
patients with docetaxel-refractory mCRPC, regardless of
PD-L1 status. Of note, the response rate was numerically
higher in patients with somatic BRCA1/BRCA2 or ATM
mutations (12%), indicating that these could be predictive
markers of response to checkpoint inhibitors. It can be seen
from Table 2.561 that testing of BRCA1/BRCA2 is NCCN
recommended. Testing of ATM is also suggested but not yet
NCCN recommended.
Gynecologic cancers
Endometrial cancers. As noted above (see Microsatellite
instability high tumors and DNA mismatch repair), the
presence or absence of MSI should be determined through
universal tumor molecular testing in every patient with
uterine cancer (see Table 2.6).62 Approximately 2% to 5%
of uterine cancers are because of Lynch syndrome, caused
by germline mutations in MLH1, MSH2, MSH6, or PMS2.
Abnormalities in MLH1 should prompt hypermethylation
testing, as this can also cause tumors to be MSI-H in
the absence of a germline mutation. The detection of a
germline mutation affects subsequent screening for colon
and ovarian cancer and prompts cascade testing to identify
other affected family members. The presence of MSI-H
because of either a germline mutation or hypermethylation
provides an indication for pembrolizumab in the setting
of recurrent uterine cancer, based on site-agnostic FDA
approval granted in 2017.13 Women with POLE-aberrant
endometrial cancers demonstrate a favorable prognosis and
may require less aggressive therapy, although this remains
theoretical at present. Identification of hotspot mutations
in genes such as BRAF, KRAS, PIK3CA, and PTEN may
correlate with biological behavior but are not yet targetable.
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TABLE 2.5. Currently Recommended Predictive Molecular Testing for Prostate Cancers
BIOMARKER

TEST DETECTS

WHEN

TECHNOLOGY

RECOMMENDATIONS

EVIDENCE

CANCER TYPE

BRCA1 and
BRCA2

Mutation
(somatic and
germline)

Initial workup: If the
patient has a strong
family history on
initial diagnosisa

NGS

A known germline mutation could help
guide therapy (eg, PARP and other DDR
enzyme inhibitors)

Lower level;
wide
acceptance

Prostate cancers

NGS

NCCN guidelines recommend inquiring about known BRCA1/BRCA2
mutations in a patient’s family for
prostate cancer early detection 61 and
Na et al63 proposed that, if a patient’s
family member died of prostate
cancer before age 75 y, a genetic
test of BRCA1BRCA/2 and ATM is
recommended

Lower levelb

Prostate cancers

If the patient has
metastatic,
castration-resistant
disease
ATM

Germline
mutation

Initial workup showing strong family
history
If patient has metastatic castrationresistant disease

Known BRCA1/BRCA2 and ATM
germline mutations could help guide
therapy with PARP and other DNA
damage–response enzyme inhibitors
Abbreviations: DDR, DNA damage repair; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; PARP, poly(adenosine diphosphate-ribose) polymerase.
a
Having at least one close relative with prostate cancer (possibility of germline mutations) and/or at least one close relative with breast, ovarian, or pancreatic
cancer (possibility of a BRCA2 germline mutation) or with colorectal, endometrial, gastric, ovarian, pancreatic, small bowel, urothelial, kidney, or bile duct cancer
(possibility of Lynch syndrome through germline mutations in MLH1, MSH2, MSH6, or PMS2) is a risk-factor.
b
Although ATM testing is not yet recommended by the NCCN as a predictive measure, Na et al63 showed that germline BRCA2 and ATM mutations distinguish
lethal from indolent prostate cancers and are associated with shorter survival times and earlier age at death. Antonarakis et al58 reported that patients with
metastatic, castration-resistant prostate cancer harboring germline mutations in BRCA1/BRCA2 and ATM have superior clinical outcomes after first-line treatment with abiraterone and enzalutamide.

TABLE 2.6. Currently Recommended Predictive Molecular Testing for Endometrial Cancers
BIOMARKER

TEST DETECTS

WHEN

TECHNOLOGY

RECOMMENDATIONS

EVIDENCE

CANCER TYPE

ESR1 (ER)

Expression

In the stage III, IV,
and recurrent
disease settings

IHC

ER positivity predicts
response to endocrine
therapy

Lower level, wide
acceptance

Uterine neoplasms,
endometrial carcinoma

PMS2 (Lynch
syndrome, MMR
gene)

Expression

Upon diagnosis or
upon recurrence if
not previously
tested

IHC

Loss of PMS2 positivity
indicates MMR, possible
Lynch syndrome, and
susceptibility to
checkpoint inhibitors

Recommended by
SGO Clinical
Practice
Statement

Uterine neoplasms,
endometrial carcinoma

Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; MMR, mismatch repair; SGO, Society of Gynecologic Oncology.

Phase 2 data demonstrate activity of mTOR inhibitors in
endometrioid carcinoma of the uterus, but these trials were
not assay-directed to determine whether molecular testing
can select for potential activity.64
Ovarian cancers. The presence of pathogenic mutations
in BRCA-related genes identify an important subset of highgrade serous epithelial ovarian cancers that have a specific
biology, natural history, and susceptibility to platinum
and PARP inhibitors. The spectrum of mutations in this
category includes those in BRCA1, BRCA2, RAD51C,
RAD51D, BARD1, BRIP1, PALB2, MLH1, MSH2, MSH6,
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PMS2, and STK11 (see Table 2.7).65-67 Patients with these
mutations have an improved prognosis with a higher
likelihood of platinum sensitivity and long-term survival.
Homologous recombination (HR)–deficient (HRD)
tumors act similarly to tumors that have BRCA-related
mutations and may serve as a surrogate for platinum
sensitivity. Identification of these mutations directly affects
therapy, as patients should be considered for treatment
with PARP inhibitors immediately after upfront therapy
with platinum and a taxane, based on the improved
progression-free survival (PFS) observed in the SOLO-1
trial (Olaparib Maintenance Monotherapy in Patients
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With BRCA Mutated Ovarian Cancer Following First
Line Platinum Based Chemotherapy; Clini
calTr
ials.gov
68
identifier NCT01844986). This international superiority
trial showed a 70% reduction in risk of ovarian cancer
progression in women with BRCA germline or somatic
mutations who received maintenance olaparib after primary
therapy with paclitaxel and carboplatin. Conversely, patients
without BRCA-related mutations may be better served
by antiangiogenic therapy with bevacizumab concurrent
with upfront platinum and taxane therapy followed by
maintenance bevacizumab therapy (Gynecologic Oncology
Group study 0218 [GOG-7]).69,70
In the recurrent setting, PARP inhibitors (olaparib and
rucaparib) as monotherapy were first approved for ovarian
cancer patients with BRCA1/BRCA2 mutations or HRD.
This indication has now been expanded to include olaparib, rucaparib, and niraparib as switch maintenance therapy for patients with platinum-sensitive ovarian cancer who
have responded to platinum in the second-line or third-line
setting.65-67,71
The identification of BRCA-related gene mutations is
also necessary to perform cascade testing on family members to identify affected family members who may be candidates for risk-reducing surgery and surveillance to prevent
subsequent ovarian, tubal, peritoneal, and breast cancer.
Evaluation of PD-1 and PD-L1 status is useful in patients
with ovarian cancer because pembrolizumab is approved
for patients with MSI-H tumors based on a site-agnostic
label. Single-agent activity for PD-1 inhibitors has been
limited in patients with ovarian cancer, but checkpoint
inhibitors are under study in the JAVELIN trials. The
combination of PARP inhibitors with checkpoint inhibitors has been investigated, and initial response rates of
25% to 30% have been noted. The larger ATHENA trial
(A Study in Ovarian Cancer Patients Evaluating Rucaparib
and Nivolumab as Maintenance Treatment Following
Response to Front-Line Platinum-Based Chemotherapy;
ClinicalTrials.gov identifier NCT03522246) of maintenance rucaparib and nivolumab therapy is currently accruing patients with ovarian cancer who have responded to
front-line, platinum-based chemotherapy.
Although initial trial results using MEK inhibitors in
the treatment of patients with low-grade serous carcinomas have been disappointing, multiple studies are ongoing
investigating MEK inhibitor monotherapy and combination therapy. Other rare ovarian cancers have different
molecular profiles, but targeted therapies remain largely
unstudied.
Cervical cancers. The treatment of patients with recurrent
cervical cancer has been problematic, and their prognosis
is dismal. Bevacizumab was approved for recurrent disease
in combination with platinums, taxanes, and topotecan;

however, no molecular markers have yet been found that
can predict patient treatment response. Pembrolizumab
was FDA-approved in 2018 for patients with recurrent and
metastatic cervical cancer who had disease progression on
or after chemotherapy and whose tumors expressed PD-L1,
based on a 14% objective response rate seen in KEYNOTE
158 (Study of Pembrolizumab [MK-3475] in Participants
With Advanced Solid Tumors; Clini
calTr
ials.gov
identifier NCT02628067). Promising data also exist for
single-agent nivolumab, which demonstrates a 26% response
rate in the recurrent setting (ClinicalTrials.gov identifier
NCT02488759). Trials evaluating combination therapy
with nivolumab and ipilimumab are currently underway.
Breast cancers
The well-established biomarkers that drive treatment decisions for patients with breast cancers are estrogen receptor
(ER) expression, progesterone receptor (PR) expression,
and human epidermal growth factor receptor-2 (HER2)
overexpression or amplification in the tumor (see Table 2.8).
Determination of ER, PR, and HER2 status is recommended for all newly diagnosed invasive breast cancers and
for any recurrences when feasible. These are routinely used
to predict response to therapy and guide treatment planning
for patients with breast cancer.
Some new markers that show promise for future use in
breast cancer are the androgen receptor (AR), ESR1, and
PD-L1. Overexpression of AR occurs in a subset of triplenegative breast cancers (TNBC).72 Clinical trials of ARtargeted treatments have shown promising preliminary
results in patients with metastatic, AR-positive TNBC.73
Mutations in ESR1 occur in the ligand-binding domain of
the ER and can lead to a ligand-independent, constitutively
active form of the ER. This is a potential mechanism of resistance to aromatase inhibitors. De novo ESR1 mutations have
been most commonly detected during or after treatment with
aromatase inhibitors for hormone receptor-positive breast
cancer.74 The treatment implication is to consider using selective ER downregulators that target ER directly in the setting of an ESR1 mutation. The role of PD-L1 as a predictive
biomarker for the treatment of patients with breast cancer
using checkpoint inhibitors will be further delineated with
several maturing trials evaluating immune checkpoint blockade in the treatment of breast cancer. In addition, multiparameter genomic assays, such as Oncotype DX (Table 2.8),
MammaPrint, and Prosigna (formerly called PAM 50),
are being used routinely for decision making in early-stage
breast cancer. MammaPrint and Prosigna are prognostic
for recurrence of tumors that are lymph node negative, have
1 to 3 positive lymph nodes, or are ER-positive but HER2negative. Additional multigene assays used for consideration of adjuvant therapy in patients with breast cancer are
EndoPredict and the Breast Cancer Index.
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Mutation

Mutation

Mutation

Mutation

Mutation

Mutation

BRCA1 and BRCA2

ATM

BRiP1

CHEK2

PALB2

RAD51C, RAD51D

Recurrent disease; initial workup if the patient
has a strong family history on initial diagnosis

Recurrent disease; initial workup if the patient
has a strong family history on initial diagnosis

Recurrent disease; initial workup if the patient
has a strong family history on initial diagnosis

Recurrent disease; initial workup if the patient
has a strong family history on initial diagnosis

Recurrent disease; initial workup if the patient
has a strong family history on initial diagnosis

Recurrent disease; initial workup if the patient
has a strong family history on initial diagnosis

WHEN

NGS

NGS

NGS

NGS

NGS

NGS

TECHNOLOGY

Include other homologous recombination pathway genes and
MSI or DNA MMR; helps guide therapy (eg, PARP or other
DDR enzyme inhibitors; chemotherapy response)

Include other homologous recombination pathway genes and
MSI or DNA MMR; helps guide therapy (eg, PARP or other
DDR enzyme inhibitors; chemotherapy response)

Include other homologous recombination pathway genes and
MSI or DNA MMR; helps guide therapy (eg, PARP or other
DDR enzyme inhibitors; chemotherapy response)

Include other homologous recombination pathway genes and
MSI or DNA MMR; helps guide therapy (eg, PARP or other
DDR enzyme inhibitors; chemotherapy response)

Include other homologous recombination pathway genes and
MSI or DNA MMR; helps guide therapy (eg, PARP or other
DDR enzyme inhibitors; chemotherapy response)

Include other homologous recombination pathway genes and
MSI or DNA MMR; helps guide therapy (eg, PARP or other
DDR enzyme inhibitors; chemotherapy response)

RECOMMENDATIONS

Lower level, wide
acceptance

Lower level, wide
acceptance

Lower level, wide
acceptance

Lower level, wide
acceptance

Lower level, wide
acceptance

Lower level, wide
acceptance

EVIDENCE

Ovarian cancer

Ovarian cancer

Ovarian cancer

Ovarian cancer

Ovarian cancer

Ovarian cancer

CANCER TYPE

Abbreviations: DDR, DNA damage repair; MMR, mismatch repair; MSI, microsatellite instability; NGS, next-generation sequencing; PARP, poly(adenosine diphosphate-ribose) polymerase.
a
Approximately 25% of ovarian cancers have germline or somatic mutations in BRCA-related or BRCA-related genes, including BRCA1, BRCA2, PALB2, BRIP1, RAD51C, and RAD51D. These tumors are targetable by PARP inhibitors, but the US Food and Drug Administration recently extended the approval of the PARP inhibitors niraparib, rucaparib, and olaparib to patients who do not express these mutations.65-67

TEST DETECTS

BIOMARKER

TABLE 2.7. Currently Recommended Predictive Molecular Testing for Ovarian Cancersa
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TABLE 2.8. Currently Recommended Predictive Molecular Testing for Breast Cancers
BIOMARKER

TEST DETECTS

WHEN

TECHNOLOGY

RECOMMENDATIONS

EVIDENCE

CANCER TYPE

ER

Expression

Noninvasive,
invasive, early
stage, metastatic

IHC

Predictor of response to
endocrine therapy

High-level,
wide acceptance

Noninvasive and invasive
breast cancer, stage I-IV

PR

Expression

Invasive, early stage,
metastatic

IHC

Predictor of response to
endocrine therapy

High-level,
wide acceptance

Invasive breast cancer,
stage I-IV

HER2

Gene
amplification

Invasive, early stage,
metastatic

ISH

Predictor of response to
HER2-targeted therapy such as
trastuzumab, pertuzumab,
lapatinib, or trastuzumab
emtansine

High-level,
wide acceptance

Invasive breast cancer,
stage I-IV

HER2 (ERBB2) Protein
expression

Invasive, early stage,
metastatic

IHC

Predictor of response to
HER2-targeted therapy such as
trastuzumab, pertuzumab,
lapatinib, or trastuzumab
emtansine

High-level,
wide acceptance

Invasive breast cancer,
stage I-IV

BRCA1 and
BRCA2

Germline
mutation

Metastatica

NGS

Predictor of response to PARP
inhibitor

High-level,
wide acceptance

Invasive breast cancer,
stage IV

Oncotype Dx

Gene
expression

Hormone
receptor-positive,
HER2-negative

RT-PCR

Prognostic for recurrence in lymph
node–negative ER-positive/
HER2-negative; predictive of
chemotherapy benefit in lymph
node–negative ER-positive/
HER2-negative

High-level,
wide acceptance

Stage I, II ER-positive/
PR-positive,
HER2-negative

Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; NGS, next-generation sequencing; ISH, in situ hybridization; PARP, poly (ADP-ribose) polymerase; PR, progesterone receptor; RT-PCR, reverse transcription polymerase chain reaction.
a
BRCA status can be assessed in early-stage disease (see National Comprehensive Cancer Network guidelines), but PARP inhibitors are not administered in
this setting. For genetic/familial high-risk assessment (breast and ovarian), the following mutations are assessed in a gene panel (these markers are primarily
homologous repair deficiency-related):

BRCA1/2

TP53

ATM

NBN

RAD51C

MLH1, MSH2, MSH6, PMS2,
EPCAM deletion

MUC16

SKT11

BRIP1

NF1

RAD51D

MLH1, MLH2, MSH6, PMS2

PTEN

CDH1

CHEK2

PALB2

CDK4/6

EPCAM (TACSTD1) deletion

Central nervous system cancers
Although broad panels are often appropriate and especially
meaningful in the metastatic setting when conventional
therapy has failed, more limited panels may be a consideration (see Table 2.975,76). This can be exemplified by central
nervous system tumors, in which genetic alterations are not
just prognostic or predictive, but diagnostic. Before 2016,
the World Health Organization (WHO) classification
relied strictly on histologic features to differentiate tumors
of astrocytic and oligodendroglial lineage.77 Although
patients have significantly different treatment paradigms
and survival depending on which of these tumor lineages
they harbor,78 occasionally features from both lineages can
be found within the same tumor, resulting in a diagnosis of
a “hybrid” oligoastrocytoma. This is further compounded by
high interobserver discordance; thus, some institutions diagnose this entity more frequently than others.79 By combining both genotype and classical histologic findings, it is
now possible to diagnose nearly all of these tumors to be
compatible with either oligodendroglioma or astrocytoma.

This has resulted in modifications to the WHO classification
in 2016 to include both histologic phenotype and molecular
genotype with consideration of IDH mutation, 1p19q
codeletion, ATRX loss, and TP53 mutation when diagnosing
gliomas.75 Furthermore, epigenetic silencing of the promoter
of the methyl-guanine methyl transferase gene MGMT
by gene promoter methylation is frequently tested
because it is highly prognostic and also predictive, correlating with a response to or benefit of alkylating agent
chemotherapy.76
It has been found that most glioblastomas have potential
actionable genomic alterations.80,81 A recent NGS analysis using a 315-gene panel found that, of 43 patients, 95%
had at least 1 therapeutically actionable genomic alteration
of a median of 4.5 genomic alterations per patient. The
most common genomic alteration detected was in EGFR
(40%). Genotype-directed treatments were prescribed
in 13 patients, representing a 30% treatment decision
impact. Treatment with targeted agents—including everolimus as a single agent and in combination with erlotinib,
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Abbreviations; FISH, fluorescence in situ hybridization; G-CIMP, glioma CPG island methylator phenotype; IHC, immunohistochemistry; NGS, next-generation sequencing; PCR, polymerase chain reaction.

Adult, low-grade, infiltrative, supratentorial
astrocytoma/oligodendroglioma;
anaplastic gliomas/glioblastoma
Lower level, limited
acceptance
Also prognostic: strongly associated with IDH75 status and genome-wide
epigenetic changes (G-CIMP); translates into a survival advantage in
glioblastoma, even in IDH wild-type tumors; used for risk stratification
in clinical trials; used in treatment decisions for elderly patients with
high-grade gliomas (grades III-IV); any patient with an MGMT
promoter-methylated glioblastoma obtains greater benefit from
treatment with temozolomide than patients without MGMT promoter
methylation
Methylationspecific PCR,
pyrosequencing
Promoter
methylation
MGMT76

Preadjuvant
therapy

Adult, low-grade, infiltrative, supratentorial
astrocytoma/oligodendroglioma;
anaplastic gliomas/glioblastoma
Lower level, limited
acceptance
Also prognostic and diagnostic: IDH1 and IDH2 mutations are related
with a favorable prognosis and help in clinical trials; infiltrative gliomas
that are wild-type IDH1 or IDH2 are likely aggressive tumors; IDH1 or
IDH2 mutations are associated with survival benefit when treated with
radiation or alkylator chemotherapy and are commonly associated with
MGMT promoter methylation
NGS, IHC
Mutation
IDH1, IDH2

Preadjuvant
therapy
glioma
workup

Adult, low-grade, infiltrative, supratentorial
astrocytoma/oligodendroglioma;
anaplastic gliomas/glioblastoma
Lower level, limited
acceptance
Also prognostic and diagnostic: helps confirm the oligodendroglial
character of tumors with ambiguous histologic features; the 1p19q
co-deletion provides a good prognosis and predicts response to
alkylating chemotherapy alone and in combination with radiation
FISH, PCR
Chromosome
deletion
1p19q
Co-deletion75

Preadjuvant
therapy

RECOMMENDATIONS
TECHNOLOGY
WHEN
TEST DETECTS
BIOMARKER

TABLE 2.9. Currently Recommended Predictive Molecular Testing for Central Nervous System Cancers

EVIDENCE

CANCER TYPE
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afatinib, palbociclib, trametinib, and BGJ398—elicited no
response.82
A fusion between Brevican (BCAN) and NTRK1 is a
potent oncogenic driver of high-grade gliomas and confers
sensitivity to entrectinib.83 A case report of a BCAN-NTRK1
fusion in glioneuronal tumors highlights its clinical importance as a novel, targetable alteration,84 and an open-label,
multicenter, global phase 2 basket study of entrectinib for
the treatment of patients with locally advanced or metastatic solid tumors that harbor NTRK1/NTRK2/NTRK3,
ROS1, or ALK rearrangements (ClinicalTrials.gov identifier
NCT02568267) is currently recruiting glioma patients.
For pediatric low-grade gliomas, BRAF V600E is a
potentially highly targetable tumor mutation, which was
detected in 17% of patients who exhibited poor outcome on
receipt of chemotherapy treatment.85 In a recent evaluation
of dabrafenib in a phase 1/2 trial that included 32 children
with relapsed or refractory, low-grade gliomas, findings
of an objective response rate of 38% and stable disease in
another 44% of patients are extremely exciting. It is encouraging that these drugs could be effective agents that allow
us to replace chemotherapy entirely for pediatric glioma.86
Other central nervous system types for which molecular
profiling has a role include ependymoma (RELA fusion),
diffuse midline cerebellar gliomas (histone 3 mutations),
medulloblastoma (WNT vs SHH activated), and ependymoma (C19MC amplification). Although many of these
tumors inevitably recur and a broader panel may be useful
at some point in the course of the disease to define clinical
trial options, obtaining a limited panel that contains the
molecular alterations considered within the WHO criteria
remains a reasonable option.
We certainly see the potential implication of molecular
profiling for a routine part of therapeutic decision making
beyond classification and prognostic prediction for patients
with glioma. Of other mutations tested, the epidermal
growth factor gene EGFR variant vIII encodes a promising
molecular target. EGFR amplification could be useful in
the treatment of glioblastomas. However, agents targeting
EGFR signaling pathways have displayed limited or no
therapeutic efficacy in glioblastoma clinical trials. ABT414 (an investigational, anti-EGFR monoclonal antibody
drug conjugate) alone87 or in combination with temozolomide showed a trend toward improved survival and was
safely administered with radiation therapy.88,89
The BRAF V600E mutation, which is analyzed using
NGS, is predictive and prognostic for low-grade pediatric
glioma. This mutation is frequently found in gangliogliomas
and in about two-thirds of grade II xanthroastrocytomas. It
is assumed that this alteration constitutively activates the
RAS/RAK/MEK/ERK kinase pathway. When BRAF
kinase inhibitor treatment effects are validated within lowgrade glioma, the drug could transform the BRAF V600E
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mutation from a diagnostic marker to predictive marker of
response to therapy.90
Sarcomas
Sarcomas are heterogeneous cancers comprising over 50
diverse histological subtypes (see Table 2.10). As a group,
they have a low occurrence incidence and are considered
rare cancers. Although there is some crossover, pediatric
and adult sarcomas have distinctly different histologies as
well as different genetic drivers. The majority of genomic
variations (translocations, CNVs, complex karyotypes, etc)
provide important predictive diagnostic information rather
than potential therapeutic targets. Thus, EWSR1-FLI1 (for
Ewing sarcoma), PAX3/PAX7-FOX01 (alveolar rhabdomyosarcoma), SYT-SSX2 (monophasic synovial sarcoma),
SYT-SSX1/SSX2 (biphasic synovial sarcoma), and TLSFUS/CHOP (myxoid liposarcoma) fusions are diagnostic
markers that should be tested at initial workup using RNA
sequencing techniques, particularly FISH. There are several prominent exceptions to this diagnosis-only rule in
gastrointestinal (GI) stromal tumors, in which mutations
in KIT (particularly exon 11) and PDGFRA are notable
biomarkers for therapeutic intervention with the tyrosine
kinase inhibitors imatinib and sunitinib.
Head and neck cancers
PD-1 is highly expressed in head and neck squamous cell
carcinomas (HNSCCs) and, in 2016, the PD-1 inhibitors
nivolumab91 and pembrolizumab92 were both approved for
the treatment of HNSCC that has metastasized or r ecurred
on or after treatment with platinum chemotherapy (see
Table 2.11). PD-L1 testing is now recommended in patients
undergoing workup for metastatic HNSCC, with the
intention of offering pembrolizumab as a treatment option
to those with PD-L1–positive tumors.

EGFR is reportedly overexpressed in between 90%
and 100% of HNSCCs.93 Accordingly, cetuximab is an
approved targeted therapy for this disease and is usually
administered regardless of EGFR mutation testing.
HNSCCs can develop resistance to cetuximab. Activation
of other EGFR family members (HER2, HER3) can play
a role in this resistance, as can c-MET, insulin growth factor receptor (IGFR), and PI3K.94 PIK3CA is frequently
mutated in HNSCC and plays a key role in the progression
of HNSCC.95,96 Targeted agents against all these markers
have been developed and have undergone or are undergoing various phases of clinical testing. Human papillomavirus
(HPV)-related HNSCCs are increasing in incidence and
have different oncogenic processes compared with HPVunrelated HNSCCs. Patients with HPV-positive HNSCCs
respond better to treatment and have a better prognosis
than their HPV-negative counterparts. Therefore, for the
sake of disease diagnosis, treatment, and management, it is
useful to accurately discriminate between the HPV-positive
and HPV-negative HNSCCs, which can be done through
tumor P16 testing by IHC; thus, P16 positivity corresponds
to HPV positivity.97
Melanomas
To date, the only FDA-approved predictive biomarker in
patients with advanced melanoma is BRAF genotyping
(see Table 2.12). Approximately one-half of melanomas
that originate from cutaneous primary sites will harbor a
BRAF V600 mutation.98 This leads to constitutive activation of the MAPK pathway and increased cell proliferation, metastasis, and survival mechanisms. Vemurafenib,
dabrafenib, and encorafenib are BRAF-targeted therapies that preferentially inhibit cells harboring the BRAF
V600 mutation. It is important to be aware that selective

TABLE 2.10. Currently Recommended Predictive Molecular Testing for Sarcomas
BIOMARKER

TEST DETECTS

WHEN

TECHNOLOGY

RECOMMENDATIONS

EVIDENCE

CANCER TYPE
a

MDM2,
CDK4a

Amplification

At diagnosis

NGS

Possible clinical trial with
CDK4/CDK6 inhibitor

Wide acceptance

IDH1/IDH2a

Mutation

At diagnosis

NGS

Possible trial with IDH1
inhibitor

Wide acceptancea

Well-differentiated liposarcoma,
dedifferentiated liposarcoma
Chondrosarcoma

Abbreviation: NGS, next-generation sequencing.
a
These tests are not strictly specified in the National Comprehensive Cancer Network guidelines but are widely accepted among the sarcoma community.

TABLE 2.11. Currently Recommended Predictive Molecular Testing for Head and Neck Cancers
BIOMARKER

TEST DETECTS

WHEN

TECHNOLOGY

RECOMMENDATIONS

EVIDENCE

CANCER TYPE

PD-L1

Protein
expression

Metastatic
workup

IHC

Recurrent, unresectable, or metastatic (with no
surgery or radiation therapy option); second-line or
subsequent therapy options: pembrolizumab for
PD-L1–positive disease

Lower level, wide
acceptance

Cancer of the
nasopharynx

Abbreviation: IHC, immunohistochemistry; PD-L1, programmed death 1 ligand.
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Melanoma
Mutation
CDKN2A

Abbreviations: AS-PCR, allele-specific polymerase chain reaction; IHC, immunohistochemistry; NGS, next-generation sequencing.

Lower level, wide acceptance;
RISK ASSESSMENT
If the individual has personal or familial incidence of 3 or more cases of
invasive melanoma or a mix of invasive melanoma, pancreatic cancer, and/or
astrocytoma, consider testing with other genes that can harbor melanomapredisposing mutations (eg, CDK4, TERT, MITF, and BAP1)
NGS

Ascertain alterations in BRAF and KIT from either biopsy of the metastases
(preferred) or archival material if targeted therapy is under consideration
NGS

IHC

Workup for
metastatic or
recurrent disease
Mutation

Protein expression

KIT

NGS, pyrosequencing, AS-PCR

Ascertain alterations in BRAF and KIT from either biopsy of the metastases
(preferred) or archival material if targeted therapy is under consideration
IHC

Gene mutation

Workup for
metastatic or
recurrent disease
Protein expression

Follow-up; risk
assessment
(predisposing
mutation)

Melanoma
Lower level, wide acceptance;
PREDICTIVE

Melanoma
Lower level, wide acceptance;
PREDICTIVE

Melanoma
Lower level, wide acceptance;
PREDICTIVE
Not recommended for patients with cutaneous melanoma who otherwise have
no evidence of disease (except to guide therapy)
NGS, pyrosequencing, AS-PCR
Gene mutation,
V600E
BRAF

Workup any time

EVIDENCE
RECOMMENDATIONS
TECHNOLOGY
WHEN
TEST DETECTS
BIOMARKER

TABLE 2.12. Currently Recommended Molecular Testing for Melanomas: Predictive and Risk Assessment Biomarkers

inhibitors of BRAF encoded by mutant BRAF V600 can
cause paradoxical activation of the MAPK pathway in cells
that are BRAF V600 wild-type (particularly if they harbor
a RAS mutation). This effect occurs through RAF dimerization, leading to increased cell proliferation rather than
inhibition.99 The combination of selective BRAF inhibitors with MEK1/MEK2 inhibitors is now FDA approved
only for patients with BRAF V600-mutant melanoma. In
patients with resected, stage III, BRAF V600E/V600K–
mutant melanoma, dabrafenib plus trametinib improves
relapse-free survival by 53%.100 Similarly, dabrafenib plus
trametinib and other BRAF/MEK inhibitor combinations
have demonstrated objective response rates of up to 68%
in patients with unresectable advanced BRAF V600E/K
mutant melanoma.101
Other oncogenic driver mutations have been identified in
melanomas for which targeted therapies have demonstrated
clinical activity. KIT mutations (and amplifications) have
been identified in up to 20% of patients with advanced melanoma, particular those with chronic sun-damaged, acral, or
mucosal melanoma subtypes.102,103 Of note, KIT mutations
are often seen across multiple exons, and hotspot mutations
are not typically observed. This patient population has a
reported response rate to imatinib of 21% to 29%.104-106
Higher response rates were seen in individuals whose melanoma harbored KIT exon 11 and 13 mutations. Another
important oncogene, NRAS, is mutated in approximately
20% of melanomas—most commonly at the Q61 position.107
Direct targeting of NRAS has proven difficult, but clinical
activity has been demonstrated by targeting the downstream
MAPK pathway with MEK1/MEK2 inhibitors. The MEK
inhibitor binimetinib showed superior clinical outcomes
compared with dacarbazine.108 However, the objective
response rate of binimetinib was only 15%, and this agent
has not yet been approved by the FDA for this indication.
With regard to predictive biomarkers for immune
checkpoint therapies in melanoma, several have shown
enrichment for greater clinical activity, mostly in post hoc
or retrospective analyses, but have not been approved by
the FDA for routine clinical use.109 These include positive
PD-L1 IHC, immune gene expression profiles, and high
tumor mutational burden (TMB) (see The role of TMB—
an emerging biomarker, below) by targeted exome sequencing. For example, response rates to anti-PD-1/PD-L1
therapy were 81%, 36%, and 10% for patients whose tumors
had >23.1 mutations per megabase (MB), 3.3 to 23.1 mutations per MB, and <3.3 mutations per MB, respectively.110
However, patients with low or negative biomarkers can
still benefit from immune checkpoint therapies, and some
studies have shown marginal differences between groups.
The PD-L1 IHC analyses from the Checkmate 067 study
demonstrate this concept well: response rates were 43%
and 58% with nivolumab monotherapy in patients whose

CANCER
TYPE
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TABLE 3. Frequency of MSI-H Status Across Cancer Typesa
% MSI-H (NO./TOTAL NO.)
VANDERWALDE 201810

CANCER TYPE

All cancer types

3.0 (342/11,348)

NSCLC (adenocarcinoma/squamous cell carcinomab)

0.6 (12/1868)

Colorectal adenocarcinoma

5.7 (80/1395)

Colon adenocarcinoma
Rectal adenocarcinoma
Pancreatic adenocarcinoma

BONNEVILLE 201711

3.8 (425/11,139)
0.5-0.6 (6/1065b)
–

–

19.7 (85/431)

–

5.73 (9/157)

1.2 (6/518)

0.0 (0/183)

Esophageal and esophagogastric junction carcinoma

0.0 (0/189)

1.6 (3/184)

Gastric adenocarcinoma

8.7 (16/184)

19.1 (84/440)

Liver hepatocellular carcinoma

2.7 (2/73)

Gastrointestinal stromal tumors (GIST)

0.0 (0/52)
c

Ovarian surface epithelial carcinoma (serous cystadenocarcinoma )

1.1 (17/1517)

Nonepithelial ovarian cancer

1.8 (1/56)

Endometrial carcinoma

0.8 (3/375)
–
1.37 (6/437c)
–

17.6 (155/879)

31.4 (170/542)

Cervical cancer (squamous cell carcinoma/endocervical adenocarcinomad)

3.6 (6/168)

2.6 (8/305d)

Breast carcinoma

0.6 (6/1024)

1.5 (16/1044)

Prostatic adenocarcinoma

2.1 (4/191)

0.6 (3/498)

Bladder cancer

0.0 (0/143)

0.5 (2/412)

Glioblastoma (multiforme)

0.7 (3/427)

0.3 (1/396)

(Skin cutaneous) melanoma

0.0 (0/345)

0.6 (3/470)

Head and neck squamous carcinoma

0.0 (0/111)

0.8 (4/510)

Sarcoma

–

0.78 (2/255)

Abbreviations: MSI-H, microsatellite instability-high; NO./TOTAL NO., number of MSI-H tumors/total number of tumor samples tested; NSCLC, non–small cell
lung cancer.
a
Data from: Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared
with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7:746-75610; and Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;1:1-15. doi:10.1200/PO.17.00073.11
b
Bonneville 2017 quoted testing lung adenocarcinoma and squamous cell carcinoma, which are subtypes of NSCLC. Vanderwalde 2018 quoted general NSCLC.
c
Bonneville 2017 quoted testing serous cystadenocarcinoma, which is a subtype of ovarian surface epithelial carcinoma. Vanderwalde 2018 quoted general
ovarian surface epithelial carcinoma.
d
Bonneville 2017 quoted testing squamous cell carcinoma and endocervical adenocarcinoma, which are subtypes of cervical cancer. Vanderwalde 2018 quoted
general cervical cancer.

tumors had <5% PD-L1 staining versus >5% PD-L1
staining, respectively.111 Biomarkers may be useful in the
application of nivolumab/ipilimumab combination therapy
over nivolumab monotherapy for patients with melanoma
based on Checkmate 067 study data. Improvement in PFS
with the combination approach was best seen in patients
whose tumors harbored a BRAF V600 mutation or had
<1% PD-L1 staining (hazard ratios, 0.62 and 0.68,
respectively).

The Gray Area Between Research and Clinical
Practice
Core clinical markers in current use by expert molecular profiling laboratories, the frequencies of these markers in a range of tumor lineages, and assay types used for
their assessment can be found in Table 6 (Caris Molecular
Intelligence). Many of the markers and their assays in
Table 6 are essentially still classified as belonging in a
“research” category, and the NCCN has not yet recommended

universal testing for these genes. Nevertheless, they have
been reported as actionable and useful by a general consensus of experts in the research community. Because the
use of broader gene panels and full-scale NGS is still in the
gray area between research and clinical practice, it comes
burdened with benefit-to-cost ratio controversies. The field
is also evolving rapidly, with fluidity existing in the classification of genes as clearly, possibly, or unlikely to be relevant
to treatment considerations.
Until recently, approved genetic testing involved a small
group of genetic tests carried out in patients with specific
cancers for a specific therapeutic purpose. Firmly established examples of mutational status being key to treatment recommendations include pan-RAS testing (KRAS,
NRAS, and HRAS) in patients with CRC to direct the use
of anti-EGFR therapies cetuximab and panitumumab45 and
HER2 testing in patients with breast cancer to direct the use
of anti–HER2-targeted therapies, such as trastuzumab,112
and tyrosine kinase inhibitor therapies, such as lapatinib.113
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TABLE 4. NTRK Frequencies in Selected Cancersa
NTRK GENE

NTRK1, n = 7

NTRK2, n = 10

NTRK3, n = 8

TUMOR TYPE

FUSION PARTNERSa

FREQUENCY (NO./TOTAL NO.)b

Gliomas

TPM3, BCAN, MEF2D

0.3% (3/982)

Colorectal carcinoma

TPM3

0.2% (2/1272)

Cervical carcinoma

TPM3

1.5% (1/68)

Lung adenocarcinoma

TPM3

0.0% (1/4073)

Gliomas

VCAN, GKAP1, KCTD8, NOS1AP, TBC1D2, SQSTM1 (n = 2),
BCR (n = 2), PRKAR2A

0.9% (9/982)

Lung adenocarcinoma

SQSTM1

0.0% (1/4073)

Gliomas

EML4, ETV6

0.2% (2/982)

Lung adenocarcinoma

ETV6

0.0% (2/4073)

Secretory carcinoma (breast)

ETV6

0.1% (1/769)

Uterine sarcoma

SPECC1L

0.2% (1/478)

Cancer of unknown primary

ETV6

0.4% (2/227)

Abbreviations: NO./TOTAL NO., number of tumors with fusion/total number of tumor samples tested.
a
These were fusion partners identified by Gatalica et al,18 and this is not a comprehensive list of all currently known NTRK fusion partners.
b
The frequency data presented here are in general consensus with previous studies, although they represent a much broader overview of frequency and types
of NTRK fusions than these other studies due to the large volume of tumors studied (more than 11,000 patients were screened). Data from: Gatalica Z, Xiu J,
Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32:147-153.2018.18

It took many years and a large number of trials involving
many patients before pan-RAS and HER2 testing became
a standard treatment-predictive approach. Other examples
of molecular testing used in standard clinical practice are
detailed above (see Disease-Specific Biomarkers). However,
as genetic testing evolved into whole genome sequencing,
advances in computer technology allowed small-capacity
assays to evolve into automated, high-throughput assays with
large-scale data collection, classification, storage, and analysis. Thus, real-time, broad gene panel testing combined with
relevant patient clinical data are now providing an unprecedented wealth of information. However, the interpretation
of the meaning of results is limited by the finding that relatively small pools of evidence are available to validate most
markers and their paired targeted therapies. Larger studies
and collaborative efforts are certainly needed to further and
more widely validate these broader panel markers and gene
expression profiles and to integrate them and their targeted
therapies into clinical practice (see Absence of Randomized,
Controlled Clinical Trials, below). The immediate goal
of testing is to translate genetic findings into potentially
effective therapy decisions for today’s patients. Meanwhile,
numerous proof-of-principle trials currently are in progress
or in development. One key to accelerating the application
of this knowledge is real-time national and international
partnerships between cancer researchers and pharmaceutical companies to perform broad-panel profiling and
elucidate targeted patient therapies. Concurrently, data pooling is mandatory using universal data-sharing capabilities to
maximize the utility of these findings and generate large
pools of evidence (see Data Sharing, below). Successes and
failures alike will provide a more complete picture, and the
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result will take us steps closer to effective cancer treatment—
and cures. This model is already in practice in the form of
basket trials.

Oncology Basket Trials and Precision Medicine
Current oncology basket trials test therapies across a range
of populations using biomarker-driven designs. Such trials choose biomarkers, which must have a clinically feasible
assay, to attempt to enrich responses to a particular targeted
therapy. The gathering of efficacy data across a range of
populations translates to only one primary outcome endpoint, which simplifies the situation while increasing deductive power. These large-scale and small-scale, broad-panel
molecular profiling trials include the National Cancer
Institute’s Molecular Analysis for Therapy Choice (NCIMATCH) trial, the American Society of Clinical Oncology
(ASCO) Targeted Agent and Profiling Utilization Registry
(TAPUR) study, and the European Organization for
Research and Treatment of Cancer–Screening Patients for
Efficient Clinical Trial Access (EORTC-SPECTA) program. These studies attempt to expand the boundaries of
precision medicine and build evidence supporting the use of
molecularly tailored therapy.

National Cancer Institute’s Molecular Analysis for
Therapy Choice Trial
The novel, phase 2 NCI-MATCH (Molecular Analysis for
Therapy Choice114) trial was initiated in August 2015 and is
bringing public and private sectors together to enable access
of physician researchers to investigational agents (in addition
to approved agents) in an attempt to build the much soughtafter evidence supporting the effectiveness of matching
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TABLE 5. Best Known Somatic Mutations That Could Also Be Germline Mutationsa
GERMLINE OR SOMATIC MUTATION

RARE GERMLINE-ASSOCIATED SYNDROME

MAIN CANCER APPLICABILITY

TP53

Li-Fraumeni

Sarcomas, and cancers of the breast and brain

MSH2, MLH1, MSH6, PMS2, EPCAM

Lynch

Cancers of the GI tract (particularly colorectal),
endometrium, ovary, brain, breast, and renal pelvis

BRCA1, BRCA2

Hereditary breast, ovarian, prostate, and
pancreatic cancers

Cancers of the breast, ovary, prostate, and pancreas

PTEN

Cowden

Cancers of the breast, endometrium, and thyroid gland

APC, MUTYH

Familial adenomatous polyposis

Cancers of the colon and rectum, small intestine,
stomach, brain, bone, and skin

CDH1

Hereditary diffuse gastric cancer

Cancers of the stomach and breast

CDK4, CDKN2A

Familial atypical multiple mole melanoma

Melanoma, pancreatic adenocarcinoma, and cerebral
astrocytoma

MEN1

Werner

Pancreatic endocrine cancer and pituitary gland tumors

RB1

Retinoblastoma

Eye cancer, pinealoma, osteosarcoma, melanomas,
and soft-tissue sarcomas

RET

Multiple endocrine neoplasia type 2

Medullary thyroid cancer, and pheochromocytoma

VHL

Von Hippel-Lindau

Kidney cancers and multiple noncancerous tumors

STK11

Peutz-Jeghers

Cancers of the breast, colon and rectum, pancreas,
and stomach and hamartomas

SDHD, SDHB, SDHC

Familial paraganglioma

Paragangliomas and pheochromocytomas

FLCN

Birt-Hoge-Dube

Chromophobe renal cell cancers

TSC1, TSC2

Tuberous sclerosis

Angiofibromas, angiomyolipomas, giant cell astrocytomas

NF1

Neurofibromatosis type 1

Optic gliomas and neurofibromas

NF2

Neurofibromatosis type 2

Schwannomas, meningiomas, gliomas, neurofibromas

PTCH1

Gorlin

Childhood primitive neuroectodermal tumors, skin basal
cell carcinomas

BMPR1A, SMAD4

Juvenile polyposis

Multiple noncancerous growths in the colon

Abbreviation: GI, gastrointestinal.
a
Table adapted from: Lartigue J. Blurring the lines between germline and somatic mutations in cancer. Oncol Live. 2017;18. onclive.com/publications/oncology-live/
2017/vol-18-no-13/blurring-the-lines-between-germline-and-somatic-mutations-in-cancer. Accessed February 6, 2019.32

targeted therapy to patient molecular profiles. The primary
aim of the NCI-MATCH study is to evaluate the proportion of patients with objective responses (ORs) to targeted
therapies predicted to be mechanistically effective based on
individual tumor genomic profiling. If the response rate to
any mutation-matched therapy is at least 25%, this match
will be tested in larger phase 2 trials. There are well over a
thousand study locations across the United States, and pharmaceutical and biotechnology companies are providing targeted agents to enrolled patients across these sites. Patients
are treated according to their profile (Table 7) and regardless of tissue origin or cancer type. New drugs of interest
can be added to the “master” trial at any time. The trial is
running under ClinicalTrials.gov identifier NCT02465060,
where up-to-date information can be obtained.

Targeted Agent and Profiling Utilization Registry
The TAPUR study is an ongoing, nonrandomized, multicenter clinical trial that opened in 2016.115 This trial

is testing the use of drugs already approved by the FDA
that target a specific tumor mutation in individuals with
advanced cancer outside of the drug’s approved indication. Patients with a range of solid tumors as well as
lymphomas and multiple myelomas are eligible for enrollment. As with NCI-MATCH, treatment assignment in
this study is based on an existing tumor mutation and not
the organ from which the cancer originated. The study
aim is to observe the real-world use of targeted therapies
in any patient whose tumor tests positive for a selected
genomic alteration that is known to be a drug target or
has been shown to predict sensitivity to a drug available in
this study. The primary outcome measure is the objective
response rate (defined as the percentage of participants in
a cohort with a complete or partial response at 8 weeks
postbaseline or with stable disease at 16 weeks or later
postbaseline according to RECIST (Response Evaluation
Criteria in Solid Tumors) (for solid tumors), international
uniform response criteria (for multiple myeloma),116 and
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Fusion

IHC

RET

PTEN

NGS

NGS

Fusion

IHC

NGS

NGS

NGS

ERBB2

KRAS

NTRK1/2/3

NTRK

PIK3CA

DDR2

AKT1

NGS

Fusion

Fusion

RET

ROS1

NGS

NGS

ALK

EGFR tertiary

ISH/fusion

ALK

EGFR T790M

Fusion

MET

NGS

CNV

MET

EGFR (exon 19
del)

165

NGS

MET

NGS

IHC

ALK

NGS

19

7792

IHC

PD-L1 (22c3)

BRAF

19

14

NGS

TML

EGFR (L858R)

10

NGS

MSI

9

0

219

35

3

1319

70

3

62

260

174

10

84

84

84

10

2541

712

10

TECHNOLOGY

POSITIVE
NO.

NSCLC

4761

4606

4606

2031

3797

4606

4606

4659

4773

4659

4659

4606

12,618

4164

4186

4164

4606

4606

4606

4606

4606

4606

5658

4557

1893

TOTAL
NO.

0.2

0.0

4.8

1.7

0.1

28.6

1.5

0.1

1.3

5.6

3.7

3.6

61.8

0.5

0.3

0.5

0.2

0.2

1.8

1.8

1.8

0.2

44.9

15.6

0.5

PERCENT

NGS

PIK3CA

NGS

NGS

IHC

IHC

IHC

PTEN

IHC

PD-L1 (SP142) IHC

TML

MSI

MSH6

MSH2

PMS2

IHC

NGS

NRAS
MLH1

NGS

BRAF

NGS
NGS

SMAD4
ATM

NGS

NGS

0

10

22

63

6

POSITIVE
NO.

252

7

1

1

187

189

189

190

3

1

4

2

10

24

42

POSITIVE
NO.

PERITONEAL CANCER
TECHNOLOGY

GNAS

KRAS

BIOMARKERS

NGS

NGS

TP53
MSI

IHC
NGS

PD-L1

NGS

TECHNOLOGY

PIK3CA

TML

BIOMARKERS

ANAL CANCER

Caris Molecular Intelligence Core Clinical Marker Frequencies for Tumor Lineages

BIOMARKERS

TABLE 6.

393

211

87

27

192

192

192

192

87

87

87

87

87

87

87

TOTAL
NO.

40

92

92

191

91

TOTAL
NO.

64.1

3.3

1.1

3.7

97.4

98.4

98.4

99.0

3.4

1.1

4.6

2.3

11.5

27.6

48.3

PERCENT

0.0

33.0

33.0

33.0

33.0

PERCENT

NGS

NRAS

PTEN

PD-L1

HER2

HER2

TML

MSI

MSH6

MSH2

PMS2

IHC

IHC

CISH

IHC

NGS

NGS

IHC

IHC

IHC

IHC

Fusion

RSPO3
MLH1

NGS

NGS

POLE

PIK3CA

NGS

NGS

KRAS
BRAF

TECHNOLOGY

BIOMARKERS

5334

196

129

161

247

83

5947

6011

5719

5840

32

14

600

285

146

1744

POSITIVE
NO.

COLORECTAL CANCER

11,407

6405

4460

8708

3400

1346

6104

6121

6097

6132

1272

3424

3427

3427

3427

3427

TOTAL
NO.

46.8

3.1

2.9

1.8

7.3

6.2

97.4

98.2

93.8

95.2

2.5

0.4

17.5

8.3

4.3

50.9

PERCENT
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NGS

NGS

IHC

NGS

NGS

NGS

NGS

NGS

MSI

TML

PD-L1

TP53

RB1

NOTCH1

RET

SMO

0

0

0

11

99

182

13

0

180

15

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

IHC

NGS

NGS

IHC

BLM

CDH1

MLH1

MSH2

MSH6

PMS2

SMAD4

BMPR1A

TP53

PTEN

APC

STK11

PD-L1

MSI

TML

HER2

75

47

17

58

30

686

7

44

2

15

3

6

50

5

31

NGS

ATM

POSITIVE
NO.

TECHNOLOGY

BIOMARKERS

1431

916

389

1804

921

922

922

922

921

921

921

921

921

922

921

921

922

TOTAL
NO.

49

206

206

206

205

206

205

88

TOTAL
NO.

GASTROESOPHAGEAL CANCER

TECHNOLOGY

POSITIVE
NO.

SMALL CELL LUNG CANCER

BIOMARKERS

TABLE 6. Continued

5.2

5.1

3.9

10.0

1.8

6.3

3.3

74.4

0.8

4.8

0.2

1.6

0.3

0.7

5.4

0.5

3.4

PERCENT

0.0

0.0

0.0

5.3

48.3

88.3

6.3

0.0

PERCENT

NGS
NGS
NGS
NGS

KRAS
NRAS
BRAF
PIK3CA

FGFR2

FGFR3

BRAF

PD-L1

HER2

HER2/neu

TML

MSI

MSH6

MSH2

Fusion

Fusion

Fusion

IHC

CISH

IHC

NGS

NGS

IHC

IHC

IHC

NGS

PBRM1

IHC

NGS

BAP1

PMS2

NGS

IDH2

MLH1

NGS

TECHNOLOGY

IDH1

BIOMARKERS

7

1

2

78

38

40

15

1

72

72

69

70

30

13

16

82

23

35

14

39

POSITIVE
NO.

CHOLANGIOCARCINOMA

149

149

131

934

618

1301

469

177

73

73

73

73

474

474

474

474

474

474

474

474

TOTAL
NO.

4.7

0.7

0.0

8.4

6.1

3.1

3.2

0.6

98.6

98.6

94.5

95.9

6.3

2.7

3.4

17.3

4.9

7.4

3.0

8.2

PERCENT

CISH
IHC
IHC

HER2
PD-L1
PTEN

Fusion

IHC

HER2

RSPO3

NGS

NGS

MSI
TML

IHC
IHC

MSH6

IHC

IHC

NGS

NGS

NGS

NGS

NGS

TECHNOLOGY

PMS2

MSH2

MLH1

POLE

PIK3CA

BRAF

NRAS

KRAS

BIOMARKERS

6

264

25

11

10

18

10

89

89

90

88

1

26

14

3

100

POSITIVE
NO.

SMALL BOWEL CANCER

57

526

342

269

482

182

71

96

96

96

96

183

183

183

183

183

TOTAL
NO.

10.5

50.2

7.3

4.1

2.1

9.9

14.1

92.7

92.7

93.8

91.7

0.5

14.2

7.7

1.6

54.6

PERCENT
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325

326

6

18

NGS

TECHNOLOGY

NGS

CDKN2A

CA: A Cancer Journal for Clinicians

BIOMARKERS

MSI

NGS

NGS

NGS

IHC

ISH

IHC

NGS

NGS

NGS

TECHNOLOGY

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NRAS

BRAF

CDKN2A

HER2

HER2

PD-L1

ATM

BRCA1

BRCA2

BIOMARKERS

MSI

TML

BAP1

FH

FLCN

MET

PBRM1

SDHD

SETD2

36

13

42

222

26

38

229

18

2

942

46

0

60

6

1

2

33

3

1

POSITIVE
NO.

RENAL CANCER

NGS

NGS

TML

KRAS

POSITIVE
NO.

PANCREATIC CANCER

78

34

168

CISH

NGS

POSITIVE
NO.

HER2

TECHNOLOGY

PIK3CA

BIOMARKERS

332

332

332

333

332

332

333

327

107

TOTAL
NO.

1031

1031

1164

2682

4063

2096

1164

1164

1164

1164

1149

456

TOTAL
NO.

922

462

1323

TOTAL
NO.

GASTROESOPHAGEAL CANCER (CONTINUED)

TABLE 6. Continued

13.9

0.0

18.1

1.8

0.3

0.6

9.9

0.9

0.9

PERCENT

3.5

1.3

3.6

8.3

0.6

1.8

19.7

1.5

0.2

80.9

1.6

1.3

PERCENT

8.5

7.4

12.7

PERCENT

IHC
IHC
IHC

PD-L1

IHC

MSH2
PMS2*

IHC

MSH6

MLH1*

NGS
CNV

HER2 (ERBB2)

NGS

NGS

NGS

NGS

Frag analysis

NGS

NGS

TECHNOLOGY

HER2 (ERBB2)

ARID1A

PIK3CA

PTEN

POLE

MSI

MSI

TML

BIOMARKERS

IHC

NGS

TML
PD-L1

NGS

NGS

MSI

ARID1A

26

4

1

8

56

53

POSITIVE
NO.

460

1912

1887

2301

2273

61

21

745

823

1137

42

267

163

282

POSITIVE
NO.

ENDOMETRIAL CANCER

NGS
NGS

CTNNB1
TP53

TECHNOLOGY

BIOMARKERS

4502

2298

2293

2306

2295

1867

1843

1841

1843

1843

1841

1831

796

1469

TOTAL
NO.

366

166

69

166

166

166

TOTAL
NO.

HEPATOCELLULAR CARCINOMA

10.2

83.2

82.3

99.8

99

3.3

1.1

40.5

44.7

61.7

2.3

14.6

20.5

19.2

PERCENT

7.1

2.4

1.4

4.8

33.7

31.9

PERCENT

NGS

NGS
NGS
NGS

BRCA2
ERCC2
FANCC
RB1

NGS

IHC
Fusion

TMPS:ERG2

NGS

AR

IHC

NGS
PD-L1

NGS

BRCA1
BRCA2

AR

NGS
NGS

TML

NGS

MSI
ATM

162

23

55

43

0

0

17

12

21

58

4

POSITIVE
NO.

57

1127

25

35

26

6

22

15

6

POSITIVE
NO.

PROSTATE CANCER
TECHNOLOGY

IHC

NGS

BIOMARKERS

PD-L1

TSC1

NGS

NGS

FGFR3

NGS

BRCA1

NGS

ATM

TML

MSI

BIOMARKERS TECHNOLOGY

BLADDER CANCER

198

1213

811

440

365

365

422

416

151

TOTAL NO.

788

364

364

364

364

364

364

364

364

361

152

TOTAL
NO.

28.8

92.9

3.1

8.0

7.1

1.6

5.2

3.6

4.0

PERCENT

20.6

6.3

15.1

11.8

0.0

0.0

4.7

3.3

5.8

16.1

2.6

PERCENT
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NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

NGS

TML

BRCA1

BRCA2

ATM

PIK3CA

PTEN

KRAS

NF1

ARID1A

SMARC4A

2

332

0.6

TECHNOLOGY

NGS

NGS

NGS

NGS

IHC

MSI

TML

TP53

PIK3CA

PD-L1
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191

92

56

20

2

POSITIVE
NO.

CERVICAL CANCER

748

4698

253

158

290

63

180

238

63

23

802

307

307

305

116

TOTAL
NO.

8693

16,353

16,384

3452

3458

3463

3463

3463

3463

3463

2922

2924

3434

1484

23.8

30.0

18.2

6.6

1.7

PERCENT

8.6

28.7

48.5

0.6

8.1

4.9

7.3

4.6

8.4

1.8

6.2

8.1

1.8

1.5

NGS
NGS
NGS
NGS

PALB2
PTEN
STK11
TP53

NGS

NGS

NBN
NF1

NGS

NGS

NGS

NGS

NGS

NGS

FLCN

ESR1

CHEK2

CDH1

BRCA2

BRCA1

NGS

CISH

HER2
ATM

IHC

HER2

IHC

PERCENT

PR

TOTAL
NO.

POSITIVE
NO.

IHC

NGS
IHC

PD-L1

TML

NGS

1203

15

143

27

86

4

3

159

32

160

88

59

50

726

900

3806

5598

5698

389

76

5

POSITIVE
NO.

BREAST CANCER

TECHNOLOGY

IHC

18.6

45.9

MSI

BIOMARKERS

AR

630

333

1.5

PERCENT

ER

117

153

332

TOTAL
NO.

OVARIAN CANCER

BIOMARKERS

IHC

NGS

MSI

PD-L1

7947

TECHNOLOGY

BIOMARKERS

IHC

IHC

PD-L1

IHC

19

NGS

VHL

ER

279

NGS

TSC2

PR

170

NGS

TSC1

5

TECHNOLOGY

BIOMARKERS

POSITIVE
NO.

RENAL CANCER (CONTINUED)

TABLE 6. Continued

2169

2164

2169

2164

2169

2164

2164

2164

2169

2164

1960

1960

2169

6087

9299

9362

9404

11,114

5519

2146

779

TOTAL
NO.

55.5

0.7

6.6

1.2

4

0.2

0.1

7.3

1.5

7.4

4.5

3.0

2.3

11.9

9.7

40.7

59.5

51.3

7

3.5

0.6

PERCENT

NGS

CIC

PDGFRA

BRAF

FGFR3

EGFR

MET

NTRK

PD-L1

EGFR

EGFRvIII

1p19q

MGMT

Fusion

Fusion

Fusion

Fusion

Fusion

Fusion

IHC

CNV

Fusion

FISH

Methylation

NGS

NGS

ATRX

FUBP1

NGS

NGS

NGS

NGS

NGS

TECHNOLOGY

TML

MSI

BRAF

IDH2

IDH1

BIOMARKERS

1

2

12

3

11

8

209

257

87

52

828

8

18

59

28

1

17

3

161

POSITIVE
NO.

GLIOBLASTOMA

404

404

404

404

404

404

1346

828

630

779

1773

851

851

851

847

265

851

851

851

TOTAL
NO.

0.2

0.5

3.0

0.7

2.7

2.0

15.5

31

13.8

6.7

46.7

0.9

2.1

6.9

3.3

0.4

2.0

0.4

18.9

PERCENT
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327

328
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3

1

NGS

Fusion

Fusion

Fusion

Fusion

Fusion

IHC

TECHNOLOGY

PDGFRA

EWSR1

RET

ALK

NTRK1

RAF1

PD-L1

BIOMARKERS

43

250

NGS

NGS

IHC

IHC

TP53

PIK3CA

PD-1

PD-L1

1

721

340

326

326

324

164

TOTAL
NO.

2386

28

469

470

469

28

1036

601

1036

1034

1025

350

TOTAL
NO.

35.4

73.5

13.2

61.7

7.4

0.6

PERCENT

21.2

3.6

0.2

0.6

0.2

10.7

0.0

0.2

4.9

6.1

3.1

1.7

PERCENT

NGS

MDM2
PD-L1

IHC

CNV

NGS

CDKN2A
PTEN

NGS

NGS

NGS

NGS

NGS

NGS

NGS

TECHNOLOGY

NRAS

NF1

MEK1

KIT

BRAF

TML

MSI

BIOMARKERS

452

16

47

111

197

189

27

20

313

289

0

POSITIVE
NO.

MELANOMA

1381

749

782

782

782

782

782

801

782

774

293

TOTAL
NO.

33.0

2.0

6.0

14.0

25.0

24.0

4.0

2.0

40.0

37.0

0.0

PERCENT

PD-L1

SF3B1

GNAQ

GNA11

BAP1

TML

MSI

BIOMARKERS

IHC

NGS

NGS

NGS

NGS

NGS

NGS

TECHNOLOGY

21

11

48

43

49

3

0

POSITIVE
NO.

UVEAL MELANOMA

139

99

99

99

99

97

22

TOTAL
NO.

15.1

11.1

48.5

43.4

49.5

3.1

0.0

PERCENT

Abbreviations: AR, androgen receptor; CISH, chromogenic in situ hybridization; CNV, copy number variation; del, deletion; ER, estrogen receptor; FISH, fluorescence in situ hybridization; Frag analysis, fragment analysis;
HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry; ISH, in situ hybridization; MSI, microsatellite instability; NGS, next-generation sequencing; NSCLC, non–small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PR, progesterone receptor; TML, tumor mutation load.

255

201

24

NGS

NGS

MSI

TML

POSITIVE
NO.

HNSCC

505

1

1

3

0

1

51

NGS

NGS

NF1

KIT

63

32

NGS

NGS

TML

NGS

MSI

RB1

6

TECHNOLOGY

POSITIVE
NO.

SARCOMA

BIOMARKERS

TABLE 6. Continued
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TABLE 7.

Broadening Molecular Profiling Boundaries—Biomarker-Targeted Therapy Matches

TARGETED MUTATION

DRUG

NCI-MATCH trial: NCT02465060a
EGFR activating mutation

Afatinib

HER2 activating mutation

Afatinib

BRCA1 or BRCA2 mutations

Adavosertib (AZD1775)

FGFR pathway aberrations

AZD4547

NRAS12, NRAS13, NRAS61 mutation

Binimetinib

AKT mutation

Capivasertib (AZD 5363)

PIK3CA mutation

Copanlisib

PTEN mutation

Copanlisib

PTEN loss

Copanlisib

MET amplification

Crizotinib

MET exon 14 deletion

Crizotinib

ALK translocation

Crizotinib

ROS1 translocation or inversion

Crizotinib

BRAF V600E/V600R/V600K/V600D mutation

Dabrafenib + trametinib

DDR2 S768R, I638F, or L239R mutation

Dasatinib

NF2 inactivating mutation

Defactinib

PTEN mutation or deletion and PTEN expression

GSK2636771 (PI3Kβ inhibitor)

PTEN loss

GSK2636771 (PI3Kβ inhibitor)

FGFR mutation or fusion

Erdafitinib

FGFR amplification

Erdafitinib

NTRK1, NTRK2, NRTK3 gene fusions

Larotrectinib (LOXO-101)

Loss of MLH1 or MSH2 (by IHC)

Nivolumab

EGFR T790M or rare activating mutation

Osimertinib

CCND1, CCND2, CCND3 amplification & Rb expression

Palbociclib

CDK4 or CDK6 amplification and Rb protein

Palbociclib

HER2 amplification ≥7 copy numbers

Pertuzumab + trastuzumab

TSC1 or TSC2 mutation

Sapanisertib

mTOR mutation

Sapanisertib

cKIT exon 9, 11, 13, or 14 mutation

Sunitinib

PIK3CA mutation

Taselisib

GNAQ/GNA11 mutation

Trametinib

BRAF fusion or BRAF non-V600 mutation

Trametinib

NF1 mutation

Trametinib

HER2 amplification

Trastuzumab emtansine

SMO/PTCH1 mutation

Vismodegib

TAPUR trial: NCT02693535b
VEGFR mutation, amplification or overexpression

Axitinib

Bcr-abl, SRC, LYN, LCK mutations

Bosutinib

ALK, ROS1, MET mutations

Crizotinib

KRAS, NRAS, and BRAF (all wild type)

Cetuximab

Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations

Dasatinib

BRCA1/BRCA2 inactivating mutations; ATM mutations/deletions

Olaparib

MSI-high, high TML, and others

Nivolumab and ipilimumab
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TABLE 7. Continued
TARGETED MUTATION

DRUG

CDKN2A, CDK4, CDK6 amplifications

Palbociclib

POLE/POLD1 mutations; high TML

Pembrolizumab

VEGFR1, VEGFR2, VEGFR3, PDGFRB, RET, KIT, RAF-1, BRAF mutations/amplifications

Regorafenib

PDGFR, VEGFR, CSF1R

Sunitinib

mTOR, TSC mutations

Temsirolimus

ERBB2 amplifications

Trastuzumab and pertuzumab

BRAF V600E mutations

Vemurafenib and cobimetinib

Abbreviations: IHC, immunohistochemistry; MSI, microsatellite instability; NCI, National Cancer Institute; TML, tumor mutation load.
a
NCI-MATCH trial: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma.
Matches are as listed on clinicaltrials.gov/ct2/show/NCT02465060. Accessed February 6, 2019. After patient tumor molecular testing on a main screening
protocol, those with actionable mutations are assigned to 1 of 35 treatment subprotocols.
b
The American Society of Clinical Oncology’s TAPUR trial: Testing the Use of US Food and Drug Administration-Approved Drugs That Target a Specific Abnormality
in a Tumor Gene in People With Advanced Stage Cancer. Matches are as listed on clinicaltrials.gov/ct2/show/NCT02693535. Accessed February 6, 2019.

Lugano criteria (for non–Hodgkin lymphoma).117,118
Table 7 details the genomic alterations (biomarkers) and
targeted therapies of interest at the time of submission of
this article for publication, although markers and therapies are continually being refined as the study progresses.
It is currently anticipated that TAPUR will enroll
over 2500 patients in total. The trial is running under
ClinicalTrials.gov identifier NCT02693535, where up-todate information can be obtained.

European Organization for Research and Treatment
of Cancer–Screening Patients for Efficient Clinical
Trial Access
EORTC-SPECTA is a collaborative European molecular screening program that coordinates several diseasespecific platforms with the aim of identifying actionable
mutations and offering specific targeted therapy to p
 atients
(ClinicalTrials.gov identifier NCT02834884).119,120 This is
a large-scale basket trial that operates through one entry
point that provides access to multiple studies and to highquality, annotated material for research purposes and
provides longitudinal follow-up of patients to understand
progression patterns.121

Targets of Special Interest: Emerging and in
Current Practice
There are several novel biomarkers of great interest, many
of which have found a niche in common practice but are
continuing to reveal exciting connections and uses. We
expand on several these markers below.

Immune Markers and Immunotherapy
Programmed death–ligand 1 expression
The immune checkpoint PD-1/PD-L1 axis is a welldescribed inhibitory pathway that leads to T-cell exhaustion in the tumor microenvironment.122 Typically, PD-1 on
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tumor-infiltrating cytotoxic T cells interacts with PD-L1
on tumor cells, causing dampening of antitumor immunity
(an adaptive immune response).123 Tumor types known to be
immunogenic typically have relatively high rates of PD-L1
positivity.124 However, although greater clinical activity
of anti–PD-1 agents (nivolumab and pembrolizumab) and
PD-L1 agents (avelumab, atezolizumab, and durvalumab) has
been consistently observed in patients with PD-L1–positive
disease,125,126 some clinical trials have found that patients
with low PD-L1–expressing tumors can derive significant
benefit from anti–PD-1/PD-L1 agents. Therefore, PD-L1
IHC score alone is insufficient for patient selection in many
tumor types. Assays have been developed to test for PD-L1
expression, including the PD-L1 IHC assay with 28-8
Dako (developed for nivolumab), 22C3 Dako (developed
for pembrolizumab), SP142 Ventana (atezolizumab), SP263
Ventana (durvalumab), and 73-10 Dako (avelumab). These
assays can be used as a tool for physicians to assess which
patients might have the largest chance of benefitting from
anti–PD-1/PD-L1 agents. However, because each inhibitor
requires its own individual PD-L1 IHC assay, it is useful to
have an upfront working knowledge of which targeted therapy is going to be used; otherwise the laboratory is required
to run 5 different IHC tests, which raises costs and inefficiencies. There are several scenarios in which the FDA
has mandated that PD-L1 positivity is required before anti–
PD-1 agents are usable within approved indications. For
example, patients with advanced, metastatic NSCLC can
be treated in the front line with pembrolizumab monotherapy only if their PD-L1 tumor proportion score (TPS) is
>50% (Table 2.1).127 In the second-line setting, pembrolizumab is FDA approved for adult patients with tumors
(eg, gastric tumors) (Table 2.342) that have a lower positive TPS score (>1%).128 Interestingly, nivolumab has been
approved as second-line therapy for select cancers regardless
of their PD-L1 status.129,130 There is controversy over the
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use and reliability of PD-L1 IHC as a predictive biomarker.
This is because of multiple factors:
• First, performing a PD-L1 IHC assay on a single tumor
site at one time point does not take into account the intrapatient tumor heterogeneity that can exist and the variability in PD-L1 expression that can occur over time.131
PD-L1 expression can be regulated by IFN-γ signaling
from T-cell interactions and by several tumor-intrinsic
pathways such as MAPK and PI3K/Akt signaling, as
well as epigenetic factors.132
• A second issue is the range of antibody assays that have
been developed124 and the need for standardization.
There have been cross assay comparisons, particularly
in NSCLC, for which the staining patterns were similar among the 28-8, 22C3, and SP142 antibodies.133,134
However, SP142 staining of tumor cell membranes was
shown to be weaker, resulting in fewer positive tumor
cells than some other assays. The 73-10 antibody was not
included in these analyses.
• A final issue is related to PD-L1 IHC scoring: how does
one define a PD-L1–positive from a PD-L1–negative
tumor? PD-L1 staining of immune cells in the tumor
microenvironment, such as macrophages, gives a signal
that is erroneously included in tumor PD-L1 assessment.
This is the case for 22C3 and SP142 assays. To date,
no approaches or thresholds reach sufficient sensitivity or specificity to be predictive of a high likelihood of
response to a given drug. Providers need to be familiar
with the individual PD-L1 assays and scoring used for
each agent and tumor type when making patient decisions based on PD-L1 results.
Microsatellite instability and deficient MMR
Microsatellites are lengths of DNA sequence that contain
single nucleotide (mononucleotide) or sections of 2 or more
nucleotide (dinucleotide, trinucleotide, tetranucleotide, or
pentanucleotide) repeats (see Microsatellite instability-high
tumors and DNA mismatch repair). When microsatellites
contain a clonal change in several repeated DNA nucleotide units, this results in MSI (tumors with such MSI are
characterized as MSI-H, and this occurs when at least one
of the MMR genes—MSH2, MLH1, MSH6, and PMS2—
are inactivated, causing dMMR).10 Since MSI-H was
established as a possible biomarker, the MSI status of a
tumor has always required microdissection and PCR-based
detection strategies. For practical purposes, MSI is equivalent to the loss of staining by IHC of at least one of the
MMR genes because any lack of normal MMR protein
expression signifies an abnormality in MMR and thus
MSI. A sensitive and specific MSI assay by NGS has
recently been developed that is comparable to the existing

gold standard of PCR-based methods without requiring
matched samples from tumor and normal tissues.10 MSI
appears to be a generalized cancer phenotype in about 4%
of all adult cancers in total. MSI-H tumors are associated with an improved prognosis in early-stage cancers. In
Table 3,10,11 MSI-H frequency data for several different cancer types are compared between 2 studies. In both studies,
patient DNA was originally sequenced by NGS; however,
the study by Bonneville et al11 obtained and retrospectively assessed sequencing data from The Cancer Genome
Atlas (TCGA), the Therapeutically Applicable Research to
Generate Effective Treatments (TARGET) database, and
444 other studies, whereas the study by Vanderwalde et al10
retrospectively assessed data from commercial comprehensive sequencing profiles performed on patient tumors
by Caris Life Sciences. It can be readily observed from
Table 310,11 that the rate of MSI-H in tumors from different tissue types is not always consistent between studies. In
particular, this can be observed for gastric cancers, endometrial cancers, breast cancers, and CRCs versus colon and
rectal cancers. These study differences could be explained
for the most part by sampling bias, the use of different data
analysis techniques, or statistical variance. Vanderwalde
et al10 certainly assessed a very sick patient population that
was undergoing tumor profiling because of a bad prognosis and lack of obvious therapeutic options, whereas the
patient population examined by Bonneville et al11 was not
described as such and possibly consisted of patients with
variable disease stages and prognoses; MSI-H patients tend
to have a better prognosis than their microsatellite stable
counterparts do, which would explain the lower percentage
of MSI-H patients in the Caris data set compared with the
TCGA data set. In addition, Vanderwalde et al10 combined
colon and rectal cases in one analysis, possibly yielding a
lower percentage of MSI-H than that seen by Bonneville
et al11 for colon cancer alone. This highlights the potential
for variability in biomarker assessment because of different assay types and technologies, not just for MSI but also
across the biomarker board.
The role of TMB—an emerging biomarker
TMB is certainly an interesting marker, and evidence
of its importance is growing. However, methodologies
assessing TMB are not widely available at present, and
most clinical laboratories do not yet offer this assessment
in their assay repertoire. Immunogenicity is certainly
associated with mutation load, suggesting that an increase
in the number of somatic mutations present in tumor cells
increases potential recognition by the immune system.135
Indeed, the presence of mutations in the tumor generates
neoantigens (not expressed by normal cells), and the more
mutations there are, the more the tumor is likely to be
immunogenic. Furthermore, emerging evidence suggests
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FIGURE 1. Venn Diagram of the Relationships Between High Tumor Mutational Burden (TMB), High Microsatellite Instability (MSI-H), and High Programmed
Death–Ligand 1 (PD-L1) for All Cancer Types.10

that a high TMB is associated with increased clinical
activity of immune checkpoint inhibitors.136-140 TMB
was shown to predict immune therapy efficacy in patients
with melanoma,138 NSCLC,140 and GI cancers.141 There
is ongoing discussion regarding the definition of “high”
TMB for predictive purposes. Most studies report ≥17
mutations per MB as high TMB, which is based on comparing TMB with MSI in patients with CRC. This, of
course, also shows that high TMB is in strong concordance with MSI-high in CRC. However, although TMB is
associated with dMMR, not all tumors with a high TMB
are actually associated with MSI-H, and future studies
should address this aspect.
MSI and MMR, TMB, and PD-L1
The relationship between TMB, MSI, and PD-L1 has
recently been explored in a broad range of cancer types
(Fig. 1).10 There is some overlap of all 3 markers in a few
cancers. However, in most cancers, overlap is infrequent or
does not exist at all, and 69.5% of all cancer cases were negative for all 3 biomarkers (7890 of 11,348 tested). A population of tumors exhibiting MSI-H status but low TMB
and no PD-L1 expression was identified. Since MSI/
MMR status alone or in combination with PD-L1 positivity became an accepted predictive marker in the FDA indication for checkpoint inhibitors, the finding that patients
can test positively for only one of these markers obviously
means that the number of patients now eligible to receive
and hopefully benefit from checkpoint inhibition has been
broadened. Until more is understood about how MSI, PDL1, and TMB work together and how this interaction is
clinically relevant, the only reasonable option is to continue
to assay for all 3 markers and ensure that the number of
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patients who are given the chance to benefit from these
drugs is maximized.
Polybromo 1
PBRM1 is a non–MSI/PD-L1/TMB marker that could
be predictive for response to checkpoint inhibitors. For
example, clear cell renal cell carcinoma (ccRCC) responds
to immune therapy but, unlike many other responsive
human tumors, harbors a low burden of somatic mutations. Even so, ccRCC has relatively high immune cytolytic activity and a microenvironment with high immune
and T-cell infiltration scores. In the past, large-scale
sequencing studies demonstrated that PBRM1 loss of
function (LOF) alterations are present in a large portion
(up to 41%) of ccRCC tumors. Patients whose tumors had
PBRM1 loss in both gene copies had significantly prolonged OS and PFS and manifested reduced tumor burden in response to immune checkpoint therapy compared
with patients without PBRM1 loss (log-rank P = .0074
and P = .029, respectively). Miao et al summarized that,
given the high prevalence of PBRM1 LOF in ccRCC, this
genetic mutation has important implications as a molecular tool for considering immune therapy responsiveness in
ccRCC and possibly across other cancer types.142

The Role of HRD as an Emerging Biomarker
Repair of DNA double-strand breaks by cells is mediated by the HR pathway or nonhomologous end-joining.
HR is a complex DNA repair pathway involving multiple
steps and has been reviewed extensively.143,144 The BRCA1
and BRCA2 genes are critical for efficient double-strand
DNA repair via HR and play an important role in the development and clinical progression of many cancers.145,146
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If a cell carries BRCA1/BRCA2 LOF mutations, it loses the
ability to repair double-strand breaks by HR and is termed
the HRD pathway. Such HRD cells are highly sensitive
to DNA-damaging agents, such as platinum-based chemotherapies and other cytotoxic agents that can cause DNA
strand breaks.147,148 PARP plays a major role in DNA strand
break repair. If PARP is inhibited, then cells ultimately die.
Thus combining cytotoxic therapy with a PARP inhibitor
can cause cell lethality.
Apart from mutations in the BRCA1 and BRCA2 genes,
there are several other mechanisms associated with HRD.
Defects in HR repair can be because of epigenetic changes
such as BRCA1 promoter methylation, somatic mutations
in key HR-related genes, and frequent copy number alterations.149 In addition, mutations in other genes may result
in HR-defective tumors and include but are not limited to
PALB2, RAD51, CHEK2, and ATM.150-153
The most common approach to test for HRD is
genomic testing for alterations in BRCA1 and BRCA2 on
the basis that BRCA1 and BRCA2 germline and somatic
mutations are known to cause HRD. Testing for additional genes involved in DNA damage repair through HR
can also be done through commercial resources. Several
other approaches have been developed to measure tumor
DNA repair function.154 The myChoice HRD test is an
NGS assay that uses DNA extracted from formalin-fixed,
paraffin-embedded or frozen tumor tissue. A tumor can
be characterized as HR-deficient or HR-nondeficient by
combining the HRD score that it generates and its BRCA1/
BRCA2 mutation status. HRD is defined as an HRD score
≥42 or the presence of a mutation in BRCA1/BRCA2. As
an example of its accuracy, the myChoice HRD assay was
seen to identify 100% of BRCA-mutated tumors and 57%
of non–BRCA-mutated tumors that had HR deficiencies
in patients with platinum-sensitive, high-grade, serous or
BRCA-mutated, recurrent ovarian cancer.65
The FoundationFocus CDx BRCA (Foundation
Medicine, Inc) assay was used to detect both germline and
somatic BRCA1/BRCA2 mutation types associated with
response to PARP inhibitor therapy.155,156 This modified
NGS-based assay determined the percentage of genomic
loss of heterozygosity, mutations in BRCA1/BRCA2, and
other HR genes in tumor tissue of patients with ovarian
cancers taking part in the ARIEL PARP inhibitor rucaparib trial. A prespecified cutoff of ≥14% for high loss of heterozygosity was determined. FoundationFocus CDx BRCA
is the first FDA-approved companion diagnostic assay for
rucaparib for the treatment of advanced ovarian cancer.
As we understand more about HRD in various cancer
types, the indications for the use of PARP inhibitors will
likely be broadened. Certain cancers, including ovarian, fallopian tube, breast, primary peritoneal, and GI (specifically

a subgroup of pancreatic adenocarcinomas and gastric/
esophageal cancers), have been shown to harbor aberrations
in genes involved in the HRD pathway. Mutations are seen
not only in BRCA1 and BRCA2 but also in other relevant
genes, such as RAD51, RAD54, DSS1, RPA1, NBN, ATR,
ATM, CHK1, CHK2, FANCD2, FANCA, or FANCC.157,158
Several PARP inhibitors have been FDA approved for the
treatment of specific types of ovarian (olaparib, rucaparib, and niraparib), fallopian tube (olaparib and niraparib),
breast (olaparib), primary peritoneal (olaparib and niraparib), and pancreatic (olaparib) cancers, but not yet for other
GI cancers. However, at present, HRD testing before
PARP-inhibitor therapy is not necessary.

Other Hot Markers in Research
Although it is not by any means an exhaustive list, some
exciting new biomarkers and their targeted therapies are
discussed below.

NTRK and Entrectinib
Entrectinib (RXDX-101) was granted a breakthrough
therapy designation by the FDA in 2017 for use as a treatment for adult and pediatric patients with NTRK-positive,
locally advanced or metastatic solid tumors who have either
progressed after prior therapies or who have no acceptable
standard therapy options (see also Neurotrophic receptor
tyrosine kinase, above).27,28 A trial studying the treatment
of patients with solid tumors (breast cancer, cholangiocarcinoma, CRC, head and neck neoplasms, melanoma, neuroendocrine tumors, NSCLC, ovarian cancer, pancreatic
cancer, papillary thyroid cancer, primary brain tumors,
renal cell carcinoma, and sarcomas) that harbor an NTRK1/
NTRK2/NTRK3, ROS1, or ALK fusion is ongoing
(ClinicalTrials.gov identifier NCT02568267). In this trial,
patients are assigned to different baskets according to tumor
type and gene fusion. The primary outcome of the study
will be the objective response rate to entrectinib.27
NTRK fusions may act as actionable targets in conjunction with other potentially targetable alterations,
such as PD-L1–positive or MSI-H status, meaning that
therapeutic combinations (TRK inhibitors plus immune
checkpoint inhibitors, for example) are a promising
strategy.159

FGFR and Erdafitinib
The fibroblast growth factor receptor (FGFR) family
comprises part of a tyrosine kinase signaling pathway that
plays a role in oncogenesis through gene amplification,
activating mutations, or translocation in several tumor
types. Erdafitinib is an orally administered FGFR family
tyrosine kinase inhibitor. Earlier this year, the FDA granted
Breakthrough Therapy Designation for erdafitinib in the
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treatment of urothelial cancer, which is based on data from
a multicenter phase 2 clinical trial focused on evaluating the
efficacy and safety of erdafitinib in the treatment of adult
patients with locally advanced or metastatic urothelial cancer
harboring specific FGFR mutations.160 The overall response
rate was 42% in 59 patients for whom data were available.160
Erdafitinib is also under investigation in the NCI-MATCH
trial as a treatment for patients with tumors that have an
FGFR mutation, fusion, or amplification (Table 7).
Also in the NCI-MATCH trial, 5 of 50 patients with an
aberrant FGFR pathway had a partial response to AZD4547
(another FGFR tyrosine kinase inhibitor).161 Two of these
patient’s tumors had point mutations in FGFR2/FGFR3,
and 2 others had FGFR3 fusions, suggesting that these particular types of mutation have increased sensitivity to the
drug, which warrants further study in this patient subtype.

MET Amplification and MET Exon 14 and Crizotinib
Aberrant activation of MET receptor tyrosine kinase signaling occurs in various cancer types as result of various MET
alterations, including amplification and an exon 14 mutation.
Crizotinib is an ALK/ROS1/MET inhibitor that is already
FDA approved in ALK-positive or ROS1-positive NSCLC
but also has proven clinical activity in cases of MET exon 14
alterations and MET amplification. Preclinical studies have
shown that inhibition of MET using crizotinib resulted
in the inhibition of growth of cancer cells that possessed
MET amplification both in vitro in cell lines and in vivo
in preclinical models.162 In an updated phase 1 analysis of
crizotinib in patients with low, medium, and high levels of
MET amplification in advanced NSCLC, patients with high
MET amplification showed clinically meaningful antitumor
activity with rapid and durable responses. Crizotinib was
generally well tolerated163 and is currently under study in
the ASCO TAPUR trial for patients with tumors that have
ALK, ROS1, or MET mutations and in the NCI-MATCH
trial as a treatment for patients with tumors that have a
MET amplification, MET exon 14 mutation, ALK translocation, or ROS1 translocation or inversion (Table 7).

mTOR and Sapanisertib (TAK-228)
The mammalian target of rapamycin (mTOR) is a kinase encoded in humans by MTOR. mTOR exists as a
core component in 2 distinct multiple-protein complexes,
TORC1 and TORC2. These complexes regulate several
different cellular processes, including cell proliferation,
cell motility, cell survival, protein synthesis, autophagy,
and transcription. Sapanisertib (TAK-228) demonstrated
a reasonable safety profile as well as promising preliminary antitumor activity in a range of tumor types with
aberrant MTOR.164 Tuberous sclerosis complex 1 and 2
(TSC1 and TSC2) mutations are also observed in certain tumor subtypes and may be targeted by sapanisertib.
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The agent is under investigation in the NCI-MATCH
trial as a treatment for patients with tumors that have
MTOR or TSC1/TSC2 mutations (Table 7).

PIK3CA and Taselisib
In the NCI-MATCH trial, 65 patients with a mutated
phosphatidylinositol 3-kinase gene (PIK3CA) were treated
with taselisib (a PIK3CA inhibitor) and, although there
were no ORs to the drug, 24% of patients had prolonged
stable disease for more than 6 months. Further research in
selected cancer types is warranted.165

CDK4/CDK6 and Palbociclib
The cyclin-dependent kinases (CDKs) CDK4 and CDK6
play a crucial role in the G1-S phase transition during
cell cycling. Palbociclib, an inhibitor of aberrant CDK4/
CDK6, is FDA approved for the treatment of hormone
receptor–positive, HER2-negative, advanced or metastatic breast cancer in combination with an aromatase
inhibitor as initial endocrine-based therapy in postmenopausal women.166 Its effect on certain GI tumors
is under investigation in the clinic.167 Palbociclib is also
under investigation in the NCI-MATCH trial as a treatment for patients with tumors that have CDK4 or CDK6
amplification or CCND1, CCND2, or CCND3 amplification (and Rb expression/protein in both study arms).
The ASCO TAPUR trial is also investigating palbociclib in the treatment of patients with tumors that harbor
CDKN2A, CDK4, or CDK6 amplifications (Table 7).

DDR2 and Dasatinib
DDR2 is a transmembrane receptor tyrosine kinase that
plays a role in cancer progression by regulating the interactions of tumor cells with their surrounding collagen matrix.
DDR2 mutations are seen in several tumor types, including lung cancer, breast cancer, brain cancer, gynecologic
cancer, and prostate cancer.168 The multikinase inhibitor
dasatinib blocks DDR2 kinase activity to various degrees
and is under investigation in the treatment of patients with
tumors that possess a DDR2 S768R, I638F, or L239R
mutation (NCI-MATCH). The agent is also under investigation in the treatment of patients with tumors that harbor Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, or
YES1 mutations (TAPUR trial) (Table 7).

Emerging Techniques

The Liquid Biopsy: Circulating Tumor Cells and
Exosomes
Peripheral blood samples are a biomarker source by way of
circulating tumor cells (DNA) and circulating nucleic acids
or associated extracellular vesicles or exosomes.169-171 The
use of liquid biopsy profiling has proven useful in selected
clinical scenarios but, to date, despite its potential in the
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management of patients with most metastatic solid tumors,
this technique has not established a firm role in standard
practice. Obvious advantages include ease of access to the
tissue through a simple blood draw. An additional advantage is that circulating samples may help reduce the problem of tumor heterogeneity as it reflects the sum total of
the tumor. However, when blood and tumor tissue are concurrently collected and analyzed, results from circulating
tumor cell analyses do not always match those obtained
from tumor tissue analyses and thus are not always reliable.
Regarding extracellular vesicles or exosomes, a newly
developed, minimally invasive ADAPT Biotargeting System
characterizes complex biological systems in their inherent
state(s) and relies on the fact that a large number of cells
in the body secrete extracellular vesicles into the circulation,
and the molecular composition of these “exosomes” correlates
with the cell of origin. Through intercellular communication, exosomes play a part in controlling many tumor progressive processes, including immune evasion, angiogenesis,
and metastasis.171 The ADAPT assay has been shown to
have potential for biomarker identification and therapeutic
use across most cancer types.171,172

Community Hospital Molecular Testing and
Assessment Program
Because 85% of cancer care is delivered in a community
setting, it is imperative that the programmatic decisions
concerning molecular testing for cancer include standardization, physician engagement, and application to
point of care. Hoag Hospital (a large community hospital in Newport Beach, California) decided to embark on
an initiative within the context of precision oncology and
identified the need for molecular testing. A committee of
interested physicians (including molecular pathologists)
and administrators was formed, and a request for proposal
was developed and put to several CLIA-certified vendors
to outsource genomic testing. Certain specific qualifications were emphasized, such as price point; turnaround
time; results reporting and support structure; portfolio of
testing, including NGS, CNV, and IHC for protein analysis and fusion genes (all preferably using disease-specific
panels); and preauthorization and billing services. Several
meetings were required to reach a final decision. Once
the vendor was selected and contracting was optimized,
all tumor molecular testing was standardized, and all
ordering and tissue processing was sent through the central pathology laboratory. It is important to note that this
process had immediate benefit for the cancer programs
because, before this arrangement, molecular testing was
haphazard. Tumor tissue samples were being sent by
individual physicians to multiple different laboratories/
vendors without standardization of tissue collection and

processing, and subsequent result reports were generally
faxed and unavailable when needed for valuable treatment
assessment in the standard clinical or research settings.
After vetting and education concerning this new molecular testing and assessment program at disease site committee and tumor board meetings, it was further decided that
genomic testing would be reflexed and ordered by pathology for selected clinical stages of solid tumors. The initial
pilot project for this reflex testing was in NSCLC stages IB
through IV. Before this initial pilot of genomic reflex testing
in lung cancer, approximately 50% of the tumors in patients
with advanced lung cancer were being tested for even the
minimal NCCN guideline biomarkers. Now, over 95% of
advanced lung cancers undergo genomic profiling evaluation
that has resulted in pervasive use at the point of care. An
illustrated example of this was a recent patient’s lung cancer
demonstrating an actionable mutation in BRAF. The success
of this pilot study in reflex profiling has expanded to other
cancer disease sites, such as advanced head and neck cancers,
ovarian cancers, glioblastoma multiforme, sarcoma, and rare
tumors. Over the past 18 months, more than 300 tumors
have undergone clinical grade genomic profiling, and those
data are readily available to the treating physician through
web access. Importantly, physician education is a key component to the establishment of a comprehensive cancer molecular genomics program. Initiation of the more routine use
of molecular markers and genomic profiling has stimulated
interest and participation in the expanding clinical applications. Along with the assistance of molecular pathology,
presentation of genomic data is now frequently requested,
and this provides points of discussion in the cancer disease
site tumor board meetings. In addition, this information has
led to optimal patient selection and a definitive increase in
referrals to the phase 1 clinical trials program.
Despite the successful implementation of this intuitional program in cancer molecular testing, challenges
remain. These fall into several categories, such as reimbursement issues, evaluating the tumor genomic data for
potential germline testing, paring results to clinical trial
opportunities, and collecting and collating the genomic
data to clinical information and outcomes, as well as the
incorporation of new opportunities such as sequencing
cell-free DNA or routine pharmacogenetic testing. The
overall goal of this program was to provide added value
and physician engagement in precision oncology. This is
now a work in progress, but we are already evaluating the
growth opportunity to enhanced patient care.

Challenges and Open Questions in Molecular
Profiling

Absence of Randomized, Controlled Clinical Trials
One of the major challenges with the use of large panels
or whole genome sequencing is the absence of randomized
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clinical trials demonstrating benefit. Although some retrospective analyses have appeared promising, in general,
the field demands more evidence given the expense of
drugs and genomic tests and potential harm from exposing patients to toxicity of drugs without proof of efficacy.
A properly performed randomized clinical trial requires a
large number of patients and needs to be a national study
requiring significant resources to cover costs of testing,
cost of drugs, and data analysis. It would be problematic
to randomize patients to genomic profiling versus no testing. It is also complicated to compare standard therapy
with molecularly assigned therapy in terms of comparing
apples to apples and defining what the valid endpoints
should be. It is clear that the gold standard is OS, but
this may be affected by multiple lines of therapy and
ultimate use of targeted therapy beyond a particular study.
PFS is a reasonable endpoint but, if the randomization
occurs at a time when there is effective standard therapy,
then the impact of molecularly targeted therapy may be
underestimated. With the era of precision oncology, there
is opportunity to break new ground in trial design. In
this regard, pooling N-of-one data that account for other
factors described below, such as tumor heterogeneity, may
allow for useful evidence to help patients even if it does
not rise to randomization. In addition, the PFS ratio as
defined by Von Hoff remains a good metric to determine
benefit of molecularly assigned therapy.

Lack of Drugs
Another major challenge is the lack of availability of drugs
for numerous drivers of various cancers. Examples of major
drivers for which there are currently no approved drugs include mutated β-catenin, mutated P53, or mutated RAS,
among others. On the optimistic side, as drugs are discovered and developed, they can be offered retrospectively to
patients who have actionable mutations. A related issue is
the lack of drugs that effectively target emergent resistance mechanisms. There are some exceptions with mutated
EGFR, ALK, or BCR-ABL.

Tumor Heterogeneity
It is clear that advanced cancers, especially those that
have been treated, harbor significant tumor heterogeneity. This includes intralesion heterogeneity, interlesion
heterogeneity, and interpatient heterogeneity, all of which
complicate treatment recommendations and outcomes of
studies.

Platform Heterogeneity
In clinical practice, there are several different available platforms for molecular profiling; each test has its
own sensitivity and specificity. The scope of the testing
varies in the number of genes, whether RNA or protein
336

CA: A Cancer Journal for Clinicians

expression is assessed, and whether actionable fusions are
readily detectable. Such heterogeneity makes it difficult
to pool data from different platforms. The various commercial platforms or those performed within academic institutions are continuously evolving, further complicating
the issue of platform heterogeneity. Thus older platforms
that did not capture actionable targets for which there are
effective therapies lead to data sets that may underestimate the value of genomic testing with respect to patient
outcomes. Moreover, no study to date has shown that
larger panels are worth doing over smaller targeted gene
panels that are part of standard of care (eg, KR AS, NR AS,
BR AF, and MSI in CRC). However, it is not unreasonable to expect that the many genomic changes representing the tail end of the curve of drivers may affect patient
outcomes, especially if there are available drugs that target their pathways. With the emergence and popularity
of liquid biopsy, this yet further adds complexity to the
platforms. Of note, in the TAPUR study, which models real-life situations, liquid biopsy is acceptable for the
identification of actionable targets to allow enrollment in
a treatment arm.
CLIA-approved laboratories offering molecular panel
analysis
Before a patient sample of any kind can be tested, the assay
in question must be validated in a CLIA-certified laboratory. CLIA defines a clinical laboratory as any facility that
performs laboratory testing on specimens derived from
humans for the purpose of providing information for the
diagnosis, prevention, or treatment of a disease or im
pairment. The CMS regulates all laboratory testing performed on humans in the United States through the CLIA
program. In total, CLIA covers approximately 260,000
laboratory entities. The Division of Clinical Laboratory
Improvement and Quality, within the Quality, Safety, and
Oversight Group under the Center for Clinical Standards
and Quality, has responsibility for implementing the CLIA
program. The objective of the CLIA program is to ensure
quality laboratory testing. Although all clinical laboratories
must be properly certified to receive Medicare or Medicaid
payments, CLIA has no direct Medicare or Medicaid program responsibilities.
Clinical laboratories must constantly evolve their test offerings to support the most recent advances in cancer care.
For NGS tumor profiling assays, there are multiple commercially available kits with similar claims for gene content and sensitivity. Many factors contribute to the decision
of which assays or customized solutions will best meet the
needs of the laboratory, clinicians, and patient population.
Kit costs, capital equipment expenditures, complexity of
workflow, and turnaround time are all important factors
that can be relatively easily compared and assessed between

CA CANCER J CLIN 2019;69:305–343

assay systems. However, the more important parameters for
determining effective, personalized treatment for patients
are accuracy, reproducibility, and sensitivity of the assay,
and these can be much more challenging to critically evaluate but must be rigorously validated.173-176 The use of a
highly multiplexed, consistent, and well-characterized reference material greatly facilitates the comparison of assay
systems.177

Data Sharing
Given the numerous challenges described above and others, including limitations of electronic medical records,
issues with intellectual property, commercial interests,
Health Insurance Portability and Accountability Act of
1996 (HIPAA) regulations, and quality of clinical outcomes data, there are major difficulties with data sharing to
expand data sets through larger sample size. In this regard,
the Caris Precision Oncology Alliance has been addressing
some of the issues through the CODE database, which is
increasing the number of patients for whom analysis of clinical outcomes is possible as a function of clinical, genomic,
or drug use. Other initiatives of national prominence include Orion, Project GENIE, the WIN Consortium,
the Precision Medicine Exchange Consortium, and the
Memorial Sloan Kettering (MSK) Cancer Alliance.

Timing
The ideal time to perform genomic testing to maximize
its therapeutic value to individual patients with cancer remains a matter of controversy, and the evidence base on
which to make recommendations is still evolving. Initially,
physicians mainly ordered testing in patients with advanced disease who had exhausted standard-of-care treatment options to help inform choices for treatment with
experimental agents. Trials are now underway in groups
of patients with earlier stages of disease. For example,
the newly activated, NCI-sponsored intergroup stage III
colon cancer adjuvant therapy trial randomizes patients to
standard adjuvant therapy with FOLFOX or FOLFOX
plus experimental treatment with a PD-1 inhibitor. Only
patients with MSI-H, stage III colon cancer will be eligible for randomization, and the eligibility determination
mandates genomic testing for defective MMR in p
 atients
with localized disease. Commercial genomic testing now
includes MSI testing in addition to a battery of genes
relevant to tumor progression. The addition of MSI
testing to these panels is a consequence of the recent
approval of pembrolizumab and nivolumab. The agents
are currently approved for the treatment of refractory
tumors of any histology that exhibit defective MMR.141

In patients with advanced cancers, it is clear that the
tumor genome continues to evolve with time and with
the pressure exerted on cells by treatments that selectively
favor the growth of treatment-resistant subclones.178
Investigators remain concerned about clonal evolution
and often will recommend rebiopsy of tumors when patients have refractory disease to ensure that the genomic
analysis used to make informed decisions about clinical
trials with targeted agents is ref lective of the t umor’s current biology.179 Others suggest testing at the first sign of
advanced disease, as the efficacy of conventional chemotherapy is variable and strategies for salvage therapy may
be required sooner rather than later. The use of “liquid
biopsies” either on circulating tumor cells or on cell-free
DNA has been touted as a method of assessing the tumor
genome without the need for a repeat, invasive biopsy.
This remains a research tool at this time and is not generally a part of clinical practice. Continued data analyses are urgently needed and will inevitably occur as more
samples are tested and the practical application of these
assessments are translated into treatment decisions.

Discussion
In 2019, optimum cancer care requires state-of-the-art
molecular diagnostics, a solid knowledge base to interpret
and apply the results, and a nearly constant awareness of
changes on the horizon. The field is moving that quickly.
Comprehensive testing performed on our patients at the
beginning of 2019 is likely to be incomplete today. Drug
approvals are no longer based solely on large phase 3 trials; these late-stage trials are being replaced by “basket” and
“umbrella” trials, allowing us to ensure that the right drug is
given to the right patient faster. Subsequent new regulatory
and payer approvals seem to come daily. Precision medicine is now a part of our standard practice, but with this
comes many new challenges. How do we deal with tumor
heterogeneity, and will liquid biopsies satisfactorily replace
tissue-based testing? Are we justified in, and can we afford,
testing a large sample of patients, knowing that we will only
rarely find the sought after “needle in the haystack?” How
do we manage our patients’ expectations when there is so
much press and hype surrounding our new discoveries? Can
we afford to develop and ultimately to pay for increasingly
expensive therapies targeting increasingly smaller proportions of patients? There is, of course, no turning back, but
there is much work ahead. ■
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